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Follicular thyroid carcinoma (FTC) is the second most common malignancy of the thyroid 
gland, with predisposing genetic alterations such as rat sarcoma (RAS) mutation and paired 
box gene 8-peroxisome proliferator-activated receptor ( (PAX-PPAR() alteration, as well 
as suggested risk factors such as iodine insu)ciency and female gender. Distinguishing 
FTC from the most common neoplasm of the thyroid, follicular thyroid adenoma (FTA), or 
even from a non-neoplastic goitrous nodule, is o*en impossible preoperatively, leading to 
unnecessary surgery and exposing patients to surgical complications.
In this study, 127 follicular thyroid neoplasia patients (83 FTAs and 44 FTCs) treated at 
Helsinki University Central Hospital (HUCH) in Finland between 1990 and 2009 were 
examined to !nd methods for di#erential diagnosis between follicular thyroid lesions. 
Tissue markers were investigated by immunohistochemistry in follicular neoplasms and 
non-neoplastic control tissues, and were correlated with clinical parameters, such as with 
metastatic disease and survival. Additionally, cancer registry data from the HUCH region 
were gathered, concerning the diminishing incidence of FTC accompanied by an increase in 
the incidence of papillary thyroid carcinoma.
Carcinomas were reanalysed according to the new World Health Organization classi!cation 
of endocrine tumours, in which a new tumour entity, poorly di#erentiated carcinoma of the 
thyroid, was introduced. Markers with possible clinical utility were found; e.g. in an attempt 
to di#erentiate between non-neoplastic and neoplastic follicular lesions of the thyroid 
(HES5) as well as between FTA and FTC (MIB-1, Cyclin D1, TLR-2, ER%), a marker with 
prognostic value in carcinomas (ER%), as well as a marker correlating with the presence of 
metastatic disease (TLR-4).
$ese results aid in the challenging !eld of diagnostics in follicular thyroid lesions. Measuring 
the expression of HES5 may help in di#erentiating between neoplastic and non-neoplastic 
follicular thyroid lesions. Markers, such as MIB-1 and ER%, are partly able to di#erentiate 
between benign and malignant follicular thyroid neoplasias, whereas ER% and TLR-4 have 





In Finland, approximately 350+400 new thyroid cancer cases are diagnosed yearly (1). 
$e most common thyroid cancer type is papillary thyroid carcinoma (PTC), a neoplasia 
showing increasing incidence, whereas follicular thyroid carcinoma (FTC) is the second most 
common type, with decreasing incidence. Both subtypes are included in the group of well-
di#erentiated thyroid carcinomas (WDTCs) with excellent 5-year survivals of over 95% and 
85% respectively (2). $e most recent classi!cation of the World Health Organization (WHO) 
of Endocrine Organs was introduced in 2004 (2), in which a new thyroid tumour entity called 
poorly di#erentiated thyroid carcinoma (PDTC) was introduced and categorized between 
WDTC and anaplastic thyroid carcinoma (ATC) according to behaviour and morphology. 
Additionally, the WHO has distinguished the follicular variant of PTC (FVPTC) from FTC 
resulting in a reciprocal decrease in incidence of FTC.
$e major risk factors for thyroid carcinoma include ionizing radiation, both therapeutic and 
accidental, de!ciency in dietary iodine, lymphocytic thyroiditis or goitre, certain hereditary 
conditions such as familial adenomatous polyposis coli in PTC and Cowden syndrome in 
both FTC and PTC, female gender, older age and diabetes (3,4). PTC especially is linked 
with ionizing radiation more o*en than other carcinoma subtypes and women are known 
to be more susceptible to it (5). $e worst historical nuclear power accident in the world in 
Chernobyl, Ukraine in 1986 increase the prevalence of thyroid carcinomas at least 10-fold. 
$is was especially seen in young children in Belarus, with the !rst cases arising in 1990. 
Children under the age of 5 years were particularly prone to develop cancer, especially PTC 
(6,7).
Malignant thyroid nodules are o*en asymptomatic, but may present as bulging of the neck 
and can even cause hoarseness, due to disturbance in laryngeal nerve function. $e gold 
standard for diagnostics of thyroid nodules includes ultrasound (US) imaging combined 
with !ne-needle aspiration biopsy (FNAB). Diagnosis of thyroid nodules is challenging, 
since cytology is o*en unable to di#erentiate between neoplastic and non-neoplastic thyroid 
nodules. $e varying criteria of thyroid neoplasias used worldwide further increases the 
challenges in the diagnosis of thyroid nodules. In Finland alone, major di#erences in the 
incidence numbers of thyroid cancers occur. For example, in the Helsinki University Central 
Hospital (HUCH) region (1 million residents), about 25 new cancer cases are diagnosed 
yearly, compared to about 16 new cases yearly in the Oulu University Central Hospital 
region (0.2 million residents) (I), (8).
Follicular thyroid adenoma (FTA) is the most common neoplasia of the thyroid, and it is 
indistinguishable from FTCs at cytology. Di#erential diagnosis between them is made at 
histology by demonstration of invasive growth through the tumour capsule or to vessels. 
Occasionally, even non-neoplastic nodules are indistinguishable from neoplastic lesions. 
$is leads to diagnostic surgery, causing unnecessary morbidity and rising healthcare 
11
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costs. Many markers have been sought to aid in thyroid diagnostics, but the National 
Cancer Institute has so far not been able to o#er any solution to this diagnostic problem, 
either by immunocytochemistry, immunohistochemistry or molecular techniques (9,10). 
$is translational thesis on follicular thyroid neoplasia focuses on markers for di#erential 
diagnosis between neoplastic and non-neoplastic lesions, as well as between benign and 
malignant follicular neoplasias.
12
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5     REVIEW  OF  THE  LITERATURE
5.1     Normal  thyroid  gland
$e adult thyroid gland is a bilobated organ weighing from 15 to 25 g, located in the neck in 
front of the larynx and trachea. $e two lobes are connected by the isthmus (Figure 1). $e 
gland is surrounded by a thin !brous capsule and is divided into lobules. $e parathyroid 
glands are located posterior to the thyroid next to the recurrent laryngeal nerves, which 
run between the trachea and oesophagus. $e blood supply to the thyroid comes from the 
superior thyroid arteries, which branch from the external carotid arteries, and the inferior 
thyroid arteries, which branch from the subclavian arteries. $e nerves running to the 
thyroid come from the superior and middle cervical sympathetic ganglia (11-13).
During embryogenesis the thyroid arises from the foramen caecum of the tongue as an 
endodermal structure and descends as a part of the thyroglossal duct, which usually atrophies, 
but remnants may be found in adults along this duct, such as in the ovaries (struma ovarii) 
(11-13).
$e thyroid lobules are composed of follicles that contain colloid in their lumina. Colloid 
contains concentrated periodic acid-Schi# (PAS)-positive thyroglobulin. $e polar-shaped 
thyroid hormone-producing follicular cells are arranged as a monolayer surrounding the 
colloid. $eir nuclei are round, containing di#use chromatin. Immunohistochemically, the 
follicular cells express thyroglobulin and thyroid transcription factor 1 (TTF-1), the building 
blocks for the thyroid hormones, low-molecular-weight keratin and vimentin.
$e second type of hormone-producing cell, the C cells, accounting for only 0.1% of the 
thyroid´s mass, may be found as small clusters in the middle to upper third of the lateral 
lobes, usually in an intrafollicular position. $e C cells produce calcitonin, a hormone 
Figure 1. Surgically removed thyroid 
gland having an enlarged right lobe with 
suspected neoplastic growth. (Image from 
courtesy of Ilkka Heiskanen)
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involved in calcium homeostasis, somatostatin and other peptides. Immunohistochemically, 
they accumulate calcitonin, TTF-1, somatostatin and neuroendocrine markers, such as 
chromogranin A and synaptophysin.
Solid cell nests are the third cell type of the normal thyroid gland and are believed to represent 
a remnant of the ultimobranchial body, from which the C cells are derived. $e biological 
signi!cance of these nests remains disputable (11-13).
$e thyroid gland is a part of the hypothalamus-pituitary-thyroid (HPT) axis, with a feedback 
system activating from the hypothalamus, producing TRH (thyrotropin-releasing hormone), 
which activates the thyrotroph cells in the anterior lobe of the pituitary gland to release TSH 
(thyroid-stimulating hormone), which in turn activates the follicular cells of the thyroid 
gland to produce thyroid hormones called triiodothyroxine (T3) and tetraiodothyronine or 
thyroxine (T4). As a negative feedback mechanism, the hormones suppress the secretion of 
both TSH and TRH. $e thyroid hormones have multiple actions in body metabolism, such 
as oxygen consumption, cardiac output and heat production.
5.2     Thyroid  neoplasia
5.2.1 Incidence of thyroid nodules
General practitioners are o*en the !rst doctors who encounter a thyroid nodule presenting 
as a bulging of the neck. $yroid nodules are common and their prevalence increases with 
age. $eir prevalence is dependent largely on the method used for detecting the nodules. 
By palpation, an average worldwide prevalence of thyroid nodules has been estimated as 
4+7% in iodine-su)cient regions (14-16), by US imaging up to 35+70% (14,16-18), and at 
autopsy from 50% to over 80% (14,16,19). With current diagnostic methods of clinically 
evident thyroid nodules, the risk of malignancy in all nodules is between 5% and 15%, 
whereas 15+20% are estimated to be benign adenomas and the rest adenomatous nodules 
(20-24). Incidentalomas, e.g. asymptomatic nonpalpable occult thyroid nodules, are 
becoming increasingly common, due to imaging of the neck for other reasons, such as 
computed tomography (CT) or angiography of the carotid arteries. $e risk of malignancy 
in incidentalomas is 5+10% (14,25). However, not all incidentalomas lead to clinical disease, 
which is supported by the large quantity of occult cancers found in autopsy studies (14,16,19).
In comparing solitary nodule and multiple nodules, the prevalence of thyroid cancer is 
reported to be identical, when the nodules examined are larger than 10 mm in diameter. 
Nonetheless, cancer may appear in smaller nodules as well (22). Others have also reported a 
similarly identical cancer prevalence in multinodular goitre (MNG) and in solitary nodules, 
but irrespective of the size of the nodule (26). Contrasting results have been presented, with 
both higher and lower numbers of malignancies encountered in cases of solitary nodule 
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versus multinodular disease (18,27). An elevated risk of malignancy in relation or incidental 
to MNG has been shown. In a review, Nixon and Simo (18) estimated the incidence of MNG 
to be approximately 10% in the population when screened by US. $e risk of occult cancer 
was estimated to be up to 10+35% in these occult MNGs. On the other hand, in a large 
meta-analysis the risk of thyroid cancer was less frequent in MNG than in a single nodule, 
in which the prevalence of thyroid cancer was estimated as 5% (27). Similar !ndings have 
been reported by other authors as well (26). Current practice considers goitre to be a benign 
disease with no need for routine follow-up.
Worldwide, thyroid cancer is the 18th most common cancer type among both genders, 9th 
in women and 21st in men, but it is the most common endocrine cancer (28). In Finland, 
thyroid cancer is the 13th most common cancer in women and 20th in men, accounting for 
2.2% of all cancers in women and 0.7% in men (29). In the United States, these proportions 
are approximately 5% and 2% (30).
Currently the population of Finland is 5.4 million and the yearly number of new thyroid 
cancer cases is 350+400 (31). In Sweden with 9.5 million residents, the number of new 
thyroid cancer cases is approximately 430 per year (32) and in Norway with 5.0 million 
residents approximately 80 per year (33). Such variance in the incidence rates among the 
Nordic countries is surprising, without any clear explanation. Di#erences between diagnostic 
practice and diagnostic criteria may have an in"uence, as well as socioeconomic factors.
$e National Cancer Institute Surveillance Epidemiology and End Results (SEER) programme 
has shown that thyroid cancer incidence rates in both genders have been increasing since 
1980 in the United States. At the same time, cancer mortality has also increased, but at a 
much slower pace (34), or has even decreased (35). In Finland during the past 10 years, the 
incidence of thyroid cancer has increased by an average of 0.5% in men and 1.4% in women 
(29). Similar !ndings, especially of the increasing incidence of papillary subtypes in women, 
have been shown in almost all continents: Europe, the Americas, Asia and Oceania (35-37). 
Decreasing rates have been reported from Sweden, Norway and Spain (36), while in the 
Netherlands, the incidence seems to remain unchanged (38). An increase in the incidence 
of PTC cases and a decrease in FTC cases were seen in the Netherlands between 1989 and 
2003 (38), whereas in Scotland the incidence of FTC increased between 1975 and 2000 (35). 
In Italy, there was no change in incidence between 1998 and 2009 (39). Interestingly, in 
Scotland the incidence in men is higher than in women (35).
In 1988, the WHO changed their histological classi!cation of PTC according to nuclear 
features, which led to a shi* of many carcinomas from FTC to FVPTC and to a decrease in 
the number of FTCs (40). FVPTC is predominantly comprised of a follicular architecture, 
with the majority of cells containing nuclei of pseudoinclusions and grooves (41). Molecular 
studies of FVPTC have shown a high prevalence of rat sarcoma (RAS) mutations, which 
are usually absent from the classical type of PTC, and a low prevalence of b-raf murine 
sarcoma viral oncogene homologue B1 (BRAF) mutations, which are o*en seen in PTC, 
thus suggesting a di#erent origin of these two lesions (42).
15
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In the United States, the most common thyroid carcinoma is PTC found as a microcarcinoma, 
mainly in patients older than 45 years (43). In Finland, microcarcinomas were detected in 
36% of the cadavers of an autopsy study (19). An increasing incidence of microcarcinomas 
has been reported along with an increase in the occurrence of tumours over 4 cm in 
diameter, demonstrating a true increase in the incidence of thyroid cancer (36). On the 
other hand, it has been suggested that evolving diagnostic methods lead to discovery of 
smaller tumours than before, and thus detection of subclinical disease without a true 
increase in the occurrence of thyroid cancer (44). $e explanation for the true increase in the 
incidence of thyroid cancer, especially PTC, may be the supplementation of iodine in food 
products, which is linked to autoimmune thyroiditis and again to PTC (45). Additionally, 
an increase in the use of bioaccumulating polybrominated diphenyl ethers (PBDEs), which 
are used as !re retardant coating matter in textiles and furniture, alters thyroid hormone 
homeostasis and causes thyroid dysfunction and tumorigenesis (46). In Finland, PBDEs are 
not manufactured, but the PBDE content of imported products is unknown (World Wildlife 
Fund, WWF). Increased exposure to external radiation, either therapeutic or accidental 
radiation, is linked to thyroid cancer (4). PTC especially is linked to ionizing radiation more 
o*en than other carcinoma subtypes and females are known to be more susceptible to it (5). 
A plausible explanation for the increasing incidence is the fact that the population is older 
than ever before in history, thus resulting in increased time to develop cancer during the 
lengthened human lifespan.
5.2.2 Classi!cation of thyroid tumours
$e classi!cation of thyroid tumours according to the WHO into benign and malignant 
lesions is presented in Table 1.
Table 1. WHO histological classi!cation of thyroid tumours 2004 (2).
  
Classification  of  Thyroid  Tumours  
Thyroid  carcinomas   Thyroid  adenoma  and  related  tumours  
Papillary  carcinoma   Follicular  adenoma  
Follicular  carcinoma   Hyalinizing  trabecular  tumour  
Poorly  differentiated  carcinoma   Other  thyroid  tumours  
Undifferentiated  (anaplastic)  carcinoma   Teratoma  
Squamous-­cell  carcinoma   Primary  lymphoma  and  plasmacytoma  
Mucoepidermoid  carcinoma   Ectopic  thymoma  
Sclerosing  mucoepidermoid  carcinoma  with  eosinophilia   Angiosarcoma  
Mucinous  carcinoma   Smooth  muscle  tumours  
Medullary  carcinoma   Peripheral  nerve  sheath  tumours  
Mixed  medullary  and  follicular  cell  carcinoma   Paraganglioma  
Spindle-­cell  tumour  with  thymus  like  differentiation   Solitary  fibrous  tumour  
Carcinoma  showing  thymus  like  differentiation   Langerhans  cell  histiocytosis  
   Secondary  tumours  
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FTA, a benign neoplasia derived from the follicular epithelium, is the most common 
neoplasia of the thyroid, with a 15+20% proportion of evident thyroid nodules (20,21). 
Radiation, iodine de!ciency and history of nodular goitre are the major risk factors for 
follicular thyroid neoplasias (15). Some genetic alterations are shown in adenomas, such as 
mutations in RAS, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (PI3KCA) and 
TSH receptor gene in toxic adenoma (15).
Clinical features
Adenomas are mainly nonfunctional. A small proportion shows autonomous hyperfunction 
(toxic adenoma), causing thyrotoxicosis. Tumours are usually found by palpation and may 
sometimes cause pressure e#ects, such as dysphagia and dyspnoea. Adenomas are !ve-fold 
more common in women than in men (15).
Histology
Microscopically, adenoma cells are regular arranged in a normo-, micro- or macrofollicular 
or trabecular growth pattern with uniform nuclear and cell morphology and rare mitotic 
cells. $e oxyphilic (Hürtle cell, oncocytic) variant of FTA exhibits brightly eosinophilic 
granular cytoplasm and large open nuclei. Other variants of FTA are FTA with papillary 
hyperplasia, signet-ring cell FTA, mucinous FTA, lipoadenoma, clear cell FTA, toxic FTA 
and atypical FTA. Macroscopically, an adenoma is surrounded by a well-demarcated and 
intact capsule, has an average diameter of 3 cm and may resemble nodular goitre (11,12).
Diagnosis
At histology, invasion through the capsule or into a vessel is absent in benign neoplasias, 
distinguishing them from FTC. $is diagnosis does not consider the possibility of a carcinoma 
in situ. $us, tumours with a disturbed morphology, such as high cellularity and nuclear 
atypia, but no invasion, are referred to as atypical adenomas (15). Distinguishing FTA from 
adenomatoid (hyperplastic) nodules is arbitrary. Consistent criteria for their di#erential 
diagnosis are lacking. Adenomas are usually solitary nodules with a well-demarcated !brous 
capsule. Adenomatous nodules are o*en multiple, lack a well-de!ned capsule and o*en 
show quite a similar morphology as the surrounding thyroid tissue (15).
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Treatment
FTA is treated with lobectomy, including removal of the thyroid isthmus. Usually, hormone 
postoperative replacement therapy is not needed, since the other thyroid lobe is preserved. 
No follow-up is needed for these patients, since current knowledge is that these tumours 
seldom recur in the preserved lobe (11-13).
Hyalinizing trabecular tumour
$is rare tumour group is of follicular cell origin, with a trabecular growth pattern and 
intratrabecular hyalinization, showing nuclear features related to PTC and rearranged during 
transfection (RET) rearrangement (RET/PTC). Microscopically, spindle cells are arranged 
in nests and psammoma bodies may be present. $is tumour is usually considered as benign, 
but its relationship to PTC awakens suspicions, as well as some reported metastasized 
tumours (47,48).
5.2.2.2  Malignant tumours
$e main subtypes of thyroid cancer include PTC and FTC (well-di#erentiated follicular 
epithelium-derived carcinomas [WDFTC]), medullary (MTC) and ATC in order of 
decreasing incidence. MTC is derived from C cells, while the other cancer types are derived 
from follicular epithelial cells. $ere is a new tumour entity called poorly di#erentiated 
follicular (PDFTC) or papillary thyroid carcinoma, with an incidence still largely unknown.
Papillary thyroid carcinoma
Accounting for up to 85% of thyroid cancers, PTC is the most common cancer subtype of 
the thyroid, with an o*en indolent course of disease with a 10-year survival of 95%. PTC 
occurs at ages 25+50 years, with female preponderance. $e clinical presentation is o*en an 
asymptomatic thyroid nodule or cervical lymph node metastasis.
$e worldwide incidence of PTC has risen for decades. $e WHO introduced a new 
classi!cation of thyroid neoplasia, in which FVPTC, with typical nuclear changes of PTC 
but with a follicular architecture, was classi!ed as a subtype of PTC instead of a subtype 
of FTC, causing an increase in the number of PTCs. More sensitive and more commonly 
used imaging techniques have also led to detection of smaller lesions than before. Papillary 
microcarcinomas are incidentally found lesions measuring 1 cm or less in diameter, which 
are o*en nonencapsulated and are similarly indolent as larger PTCs.
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Distinct genetic alterations unique for PTC have been found. $e RET/PTC fusion protein 
is seen in 20+40% and neurotrophic tyrosine kinase, receptor, type 1 (NRTK1) mutation in 
5+10%. BRAF gain-of-function mutation is seen in 30+50 % of PTCs, causing overactivation 
of the mitogen-activated protein (MAP) kinase pathway, leading to changes in cell growth, 
proliferation and di#erentiation.
Macroscopically, PTC may be encapsulated or in!ltrate the surrounding tissues, showing 
!brosis, calci!cations and cysts. Histologically well-formed papillae and o*en psammoma 
bodies (concentrically calci!ed structures within the cores of papillae) are seen, as well 
as typical nuclear changes, which are hallmarks for cytological diagnosis of PTC, such as 
nuclear grooves and inclusions, and ground-glass nuclei (Orphan Annie eye). An invasion 
into the lymphatic vessels is typical for PTCs and lymph node metastases are seen in up to 
25% of patients (41).
Follicular thyroid carcinoma
Epidemiology
FTC is the second most common thyroid cancer accounting for 10+15% of all thyroid cancers. 
Like PTC, it belongs to the group of WDTCs. FTC is three-fold more common in women, 
with occurrence peaking in the !*h decade, at slightly older age than in PTC patients. An 
average 5-year survival of FTC patients is 85+95%, depending on the aggressiveness of the 
tumour (49). In the developed countries the incidence of FTC has decreased, partly due to 
iodine supplementation in the diet, since iodine de!ciency is an acknowledged risk factor 
for FTC. $e WHO classi!cation distinguishing FVPTC from FTC and categorizing them 
as belonging to the PTC group of carcinomas has decreased the incidence rates of FTC (49).
Symptoms
Typically, FTC presents as an asymptomatic slowly growing nodule in the neck with normal 
thyroid function. Local spread to the surrounding tissues may cause hoarseness, dysphagia 
and dyspnoea. Lymphatic spread is uncommon, while hematogenous spread is seen 
primarily to the bones, lungs or liver. $e oxyphilic variant typically recurs in the neck and 
metastasizes more o*en than the conventional type (49).
Histology
FTCs are typically round or oval and are thickly encapsulated. Macroscopically, the tumours 
are light brown to pink in cut section, and areas of haemorrhage, necrosis and !brosis may 
be evident. Microscopically, these carcinomas are usually quite uniform and hypercellular, 
showing some follicle formation with colloid, while a widely invasive subtype o*en presents 
with a solid or trabecular growth pattern. $e tumour cells lack the nuclear features 
speci!c for PTC. Immunohistochemically, the cells are almost always thyroglobulin- and 
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TTF-1-positive indicating their well-di#erentiated status. $e Hürtle cell variant of FTC is 
composed of oxyphilic cells with a typical appearance of abundant granular and eosinophilic 
cytoplasm !lled with swollen mitochondria with scant or absent colloid. Clear cell change 
may be prominent in oncocytic neoplasias (40).
FTCs are divided into two categories: minimally invasive and widely invasive. $e minimally 
invasive category includes tumours with focal capsular and/or vascular invasion.  In widely 
invasive tumours, both capsular and vascular invasions are extensive. Capsular invasion 
protrudes through the entire thickness of the capsule. It should be distinguished from the cut 
made by FNAB. Vascular invasion is de!ned as evidence of tumour cells invading a vessel or 
cells inside a vessel surrounded by endothelial cells, in a vessel of the capsule or immediately 
around it. $e tumour-node-metastasis (TNM) classi!cation is used to determine the stage 
of the tumour (40) (Table 2,3).
  
Classification  of  Thyroid  Tumours  
Thyroid  carcinomas   Thyroid  adenoma  and  related   umours  
Papillary  carcinoma   Follic lar   denoma  
Follicular  carcinoma   Hyalinizing  trabecular  tumour  
Poorly  differentiated  carcinoma   Other  thyroid  tumours  
Undifferentiated  (anaplastic)  carcinoma   Teratoma  
Squamous-­cell  carcinoma   Primary  lymphoma  and  plasmacytoma  
Mucoepidermoid  carcinoma   Ectopic  thymoma  
Sclerosing  mucoepidermoid  carcinoma  with  eosinophilia   Angiosarcoma  
Mucinous  carcinoma   Smooth  muscle  tumours  
Medullary  carcinoma   Peripheral  nerve  sheath  tumours  
Mixed  medullary  and  follicular  cell  carcinoma   Paraganglioma  
Spindle-­cell  t mour  with  thymus  like  differentiation   Solitary  fibrous  tumour  
Carcinoma  showing  thymus  like  differentiation   Langerhans  cell  histiocytosis  
   Secondary  tumours  
  
TNM  Classification  
T  -­  Primary  tumour  
TX   Primary  tumour  cannot  be  assessed  
T0   No  evidence  of  primary  tumour  
T1   Tumour     2cm  in  greatest  dimension,  limited  to  the  thyroid  
T2   Tumour  >  2cm,  but     4cm  in  greatest  dimension,  limited  to  the  thyroid  
T3   Tumour   >   4   cm   in   greatest   dimension,   limited   to   the   thyroid   or   any   tumour   with   minimal  
extrathyroidal  extension,  e.g.  extension  to  sternohyoid  muscle  or  perithyroid  soft  tissue  
T4a   Tumour  of  any  size  extending  beyond  the  thyroid  capsule  to  invade  subcutaneous  soft  tissues,  larynx,  
trachea,  oesophagus,  or  recurrent  laryngeal  nerve  
T4b   Tumour  invades  prevertebral  fascia  or  encases  carotid  artery  or  mediastinal  nerves  
     
All  anaplastic  tumours  are  considered  T4  
T4a   Intrathyroid  -­  surgically  resectable  
T4b   Extrathyroid  -­  surgically  unresectable  
     
N  -­  Regional  lymph  nodes  
Regional  lymph  nodes  are  the  central  compartment,  lateral  cervical  and  upper  mediastinal  nodes  
NX   Regional  nodes  cannot  be  assessed  
N0   No  regional  lymph  node  metastasis  
N1   Regional  lymph  node  metastasis  
N1a   Metastasis  to  level  VI  (pretracheal,  paratracheal  and  prelaryngeal/Delphian)  lymph  nodes  
N1b   Metastasis  to  unilateral,  bilateral  or  contralateral  cervical  or  superior  mediastinal  lymph  nodes  
     
M  -­  Distant  metastasis  
MX   Distant  metastasis  cannot  be  assessed  
M0   No  distant  metastasis  
M1   Distant  metastasis  
Table 2. $e TNM classi!cation of thyroid carcinomas (40).
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Papillary  or  follicular  carcinomas  (under  45  years)  
Stage  I   Any  T   Any  N   M0  
Stage  II   Any  T   Any  N   M1  
Papillary  or  follicular  carcinomas  (45  years  and  older)  
Stage  I   T1   N0   M0  
Stage  II   T2   N0   M0  
Stage  III   T3   N0   M0  
   T1   N1a   M0  
   T2   N1a   M0  
   T3   N1a   M0  
Stage  IV  A   T4a   N0   M0  
   T4a   N1a   M0  
   T1   N1b   M0  
   T2   N1b   M0  
   T3   N1b   M0  
   T4a   N1b   M0  
Stage  IV  B   T4b   Any  N   M0  
Stage  IV  C   Any  T   Any  N   M1  
Differential  diagnostics
$e group of follicular thyroid neoplasias includes both benign FTA and malignant FTC. 
Using current diagnostic methods distinguishing between these lesions is challenging. In 
cytology, they are both classi!ed as follicular neoplasia, because no su)cient traits or markers 
are available for di#erentiation. Non-neoplastic lesions, such as adenomatoid nodules, may 
be mistaken for FTC if only cytological features are assessed. $e diagnosis of FTC is made 
at histology by demonstration of a distinct capsulo- or vasculoinvasion. Occasionally, even 
morphological examination o*en misses a de!nite diagnosis. For example, according to this 
criterion, remaining in situ carcinomas cannot be found, with the only option being to wait 
for them to grow and eventually invade the surroundings (11,12).
Used alongside of routine examination, immunohistochemistry currently provides only 
mind bomb E3 ubiquitin protein ligase 1 (MIB-1/Ki-67) to aid in the di#erentiation between 
FTA and FTC (50). Numerous other markers have been studied, such as galectin-3, thyroid 
peroxidase (51), dipeptidyl peptidase 4 (DPP IV) (52), HBME-1 and cytokeratin-19 (CK-
19) (53), to di#erentiate between FTA and FTC. None have shown enough diagnostic power 
to be recommended for clinical use (9,10).
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Recently, molecular testing was shown to improve diagnostic sensitivity as well as cost-
e#ectiveness, since it aids in preventing unnecessary diagnostic lobectomies (54). Molecular 
markers such as BRAF, RAS, RET/PTC or PAX8-PPAR( are recommended for testing in 
lesions with indetermined cytology. Currently, no molecular marker can predict a benign 
disease (55,56). BRAF, RET/PTC and RAS mutations are seen in 70% of PTCs, PAX8-
PPAR( in 35+80% of FTCs and RAS mutation in 40+50% of FTCs. RAS mutation is also 
seen in 20+40% of FTAs and 10+20% of FVPTCs (57,58). $ese markers can predict thyroid 
malignancy with up to 100% certainty (positive predictive value), except for the RAS and 
PAX8-PPAR( mutations, which were also evidenced in FTAs. Such adenomas are believed 
to represent precursors for FTCs or in fact be in situ carcinomas or misdiagnosed FTCs, 
since these mutations are acknowledged as potent oncogenes and capable of promoting 
malignant transformation (57-60). $e PAX8-PPAR( rearrangement is associated with 
angioinvasion in FTC. Accordingly, if a hyperplastic nodule harbours a RAS mutation, it 
should be considered a true neoplasia (57,58)  (Table 4).
Table 4. Prevalence of molecular mutations in thyroid carcinomas. Modi!ed from (61).
  
Papillary  carcinoma   Prevalence  (%)  
BRAF   45  
RET/PTC   20  
RAS   10  
TRK   <5  
Follicular  carcinoma     
RAS   45  
PAX8-­PPAR    35  
PI3KCA   <10  
PTEN   <10  
Poorly  differentiated  carcinoma     
RAS   35  
b-­Catenin   20  
TP53   20  
BRAF   20  
AKT1   15  
Anaplastic  carcinoma     
TP53   70  
b-­Catenin   60  
RAS   50  
BRAF   20  
PI3KCA   20  
PTEN   >10  
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Molecular testing of multiple alterations may be used to classify undetermined FNAB cases 
as low- and high-risk categories, thus increasing diagnostic accuracy (61). However, the 
diagnostic utility of molecular testing faces major obstacles, the most important being that 
morphology is lost during processing. Indeed, currently the best diagnostic accuracy seems 
to be obtained with traditional morphology (10). Moreover the number of cells needed is 
considerably high and unlikely to be obtained from every FNAB sample (62), not to mention 
that molecular testing su#ers from high costs and is time-consuming.
Treatment
In the case of a suspected follicular neoplasia at cytology, a lobectomy of the thyroid gland is 
performed and diagnosis of FTC is made at histology. $e treatment for FTC includes total 
thyroidectomy followed by I131 ablation to eradicate any tumour cells remaining, as well 
as normal thyroid cells, a*er surgery. $e treatment is continued with high-dose thyroxin 
treatment to suppress TSH levels to a minimum, due to growth factor abilities of TSH on 
remaining tumour cells in the body. Additional surgery and radioiodine, radiotherapy and 
chemotherapy may be administered in metastatic diseases.
Prognosis
$e prognosis for patients with the minimally invasive subtype of FTC is excellent; 5-year 
survival is over 90%. $e prognosis for widely invasive FTC is dependent on the extent of the 
disease and the presence of distant metastases, decreasing the 5-year survival to 50% (11,49).
Poorly di#erentiated thyroid carcinoma
$is cancer subtype, also known as insular, solid or trabecular carcinoma, was !rst introduced 
in 2004 by the WHO, distinguishing it from well-di#erentiated and undi#erentiated 
carcinomas of the thyroid as an intermediate between them both histologically and 
behaviourally. PDTC may emerge from either PTC or FTC, and accordingly the entire 
tumour should be diagnosed as poorly di#erentiated, even if only a small proportion of 
it exhibits poor di#erentiation traits, because some of these tumours behave like PDTC 
(63,64). $e estimated incidence is 4+7% of all thyroid carcinomas. PDTC o*en presents 
with metastases to the lungs, liver or bone and has a 5-year survival of approximately 50% 
(65).
PDTC is a tumour showing a solid, trabecular or insular growth pattern, with convoluted 
nuclei, high mitotic activity or tumour necrosis (66). $e tumours show high cellularity and 
scant colloid. $e nuclei are bland, containing !ne chromatin and small nucleoli, but focal 
nuclear pleomorphism may be present. Necrosis and mitoses are common, while atypia are 
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mild compared with that of ATCs. A limited amount of follicular cell di#erentiation, e.g. 
thyroglobulin and TTF-1 immunoreactivity, is present.
Anaplastic thyroid carcinoma
ATC, e.g. undi#erentiated carcinomas, develop from the follicular epithelium and account 
for less than 5% of thyroid carcinomas. Genetic alterations, such as loss-of-function mutation 
in the TP53 gene, are commonly found. $e 5-year survival is poor, ranging from 0% to 14% 
(67). $e clinical course is aggressive, with a rapidly growing tumour in the neck, which at 
the time of diagnosis has o*en in!ltrated to the surrounding tissues or metastasized to the 
lungs, bone or brain. ATC is more commonly seen in the elderly and has an even gender 
distribution. Histologically, the tumours appear with extensive mitotic activity, necrosis and 
high cellularity. Immunohistochemically, markers of di#erentiation, such as thyroglobulin, 
are expressed focally if at all.
Medullary carcinoma
MTC, which constitutes about 5% of thyroid carcinomas, is derived from C cells and is 
considered a neuroendocrine neoplasia. It secretes calcitonin, and elevated concentrations 
may be measured from the blood, while the tumours are calcitonin-positive at 
immunohistochemistry. MTC may be either sporadic or familial, the latter being part of 
the multiple endocrine neoplasia 2 (MEN2) syndrome. An average 5-year survival is 
approximately 80% (68).
5.2.3 Diagnosis and treatment of thyroid cancer
$e current practice of managing a thyroid nodule, either incidental or symptomatic, is 
to perform high-resolution US including FNAB, and to evaluate the levels of TSH and T4. 
A neoplastic growth is most o*en presented in conjunction with euthyroidal hormone 
status. Hypo- or hyperthyreosis causes cell abnormality and nodular formation, which 
are o*en reversible, once the patient is treated. An elevated TSH level has been associated 
with an increased risk of malignancy (69), and the American $yroid Association (ATA) 
recommends evaluation of such nodules (70). On the other hand, contrasting results have 
been shown (71).
To characterize a nodule, selective US targeting is used for improving the adequacy of 
the sample and increasing the accuracy by inserting the needle into a solid portion of the 
nodule. $e nodules are evaluated for size, internal content (cystic, solid), shape, appearance 
of the nodule margin, presentation of a halo surrounding the tumour, echogeneity, 
calci!cations, extracapsular invasion and tumour vascularity with a doppler device. 
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Cervical lymphadenopathy is also evaluated. Suggestive of malignancy is a hypoechoic 
solid nodule representing an irregular/spiculated margin without a halo surrounding it, 
showing intratumoral vascularity and microcalci!cations. A taller-than-wider shape is also 
a malignant feature, since cancer tends to grow in a centrifugal way, while benign nodules 
grow parallel to the tissue surface. A diameter over a cut-point of 1 cm of the thyroid nodule 
size may be an indication for biopsy. Nodules below this diameter should be assessed in cases 
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tissues, hoarseness, elevated TSH level, lymphadenopathy, head and neck irradiation, 
exposure to ionizing radiation, positive family history or a thyroid cancer syndrome) or 
suspicious !ndings on the US examination previously mentioned or multifocality, bilaterality 
or increase in size during follow-up (21,55,70,72). Smaller nodules should only be followed 
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Figure 2. Flow chart introducing a management recommendation in thyroid ultrasonography and !ne-
needle biopsy. US = ultrasonography, AUS = atypia of undetermined signi!cance, FLUS = follicular lesion of 
undetermined signi!cance. Modi!ed from (21,70,72).
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Recent studies have shown that the size requirement for FNAB indication should be 
reassessed. Some studies showed that even nodules at least 4 mm in size should be biopsied 
irrespective of their clinical or US characteristics, because a considerable number of such 
microcarcinomas were shown with the BRAFV600E mutation, a molecular marker linked to 
aggressiveness in PTC, or aggressive traits such as nodal metastases (54,74-76).
FNAB is the method of choice in diagnosing thyroid nodules. Large-needle or core-needle 
biopses are to be avoided because the thyroid gland is a highly vascularized organ with 
the risk of bleeding and local pain, and no extra bene!t is gained compared with use of 
FNAB. On the other hand, some studies showed that a*er one FNAB with inconclusive 
results (nondiagnostic or atypia of undetermined signi!cance (AUS) or follicular lesion of 
undetermined signi!cance (FLUS), core-needle biopsy would be more useful than repeated 
FNAB for reducing the frequency of inconclusive diagnostic results (73,77).
FNAB is useful for diagnosing PTC. On the other hand, follicular neoplasias present 
a challenge, since FTC and FTA cannot be di#erentiated at cytology. Because of limited 
sensitivity and speci!city, FNAB su#ers from a considerable number of false-negative and 
false-positive results leading to unnecessary surgery (78). $e majority of FNABs performed 
show a benign tumour (60+80%), 10-20% a follicular lesion, 10+15% are nondiagnostic, up 
to 10% are suspected malignancies and up to 10% are malignant at cytology (54,73).
Due to diversity in terminology and morphologic criteria in FNAB assessment, a new 
classi!cation system for reporting thyroid cytology was introduced in 2010 ($e Bethesda 
System for Reporting $yroid Cytopathology, (79) (Table 5). $is system increases the 
cytologic-histologic correlation and o#ers recommendations for clinical management of 
thyroid nodules.
A follicular neoplasia is counted in two of Bethesda´s categories. $e preferred category 
is follicular neoplasm or suspected follicular neoplasia, which holds a 15+30% risk of 
malignancy, mainly due to FTC or FVPTC. $e majority of cases in this category are 
FTAs or adenomatoid nodules of MNG. $e purpose of this category is to triage an FTC 
to surgery. Cytologically, the architecture of the cells is atypical, the cells are arranged in 
a crowded microfollicular or trabecular manner and the nuclear features of PTC in their 
slightly enlarged nuclei are absent. A low mitotic number is normally seen. If the majority 
of the cells of the biopsy show Hürtle cell-type features, about 15+45% of such nodules are 
evidenced malignant (79).
Additionally, follicular neoplasias may be classi!ed in the category of AUS or FLUS, which 
is used when the sample cannot be classi!ed in any distinct category. Although this category 
may cause anxiety to patients and clinicians before better neoplasia-speci!c markers are 
found, it is of great value as a follow-up and repeated biopsy may reveal the true nature of the 
lesion. $us, both unnecessary surgery, due to false-positive cases, as well as true neoplasias 
presenting as false-negative cases, can be diminished, using the AUS category (79).
Once a patient with a thyroid nodule is directed to surgery, the management is individualized 
with disease staging and risk factors are taken into account (Table 2). In the case of a 
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Nondiagnostic  or  Unsatisfactory   1 4   New  biopsy  
Cyst  fluid  only  
Virtually  acellular  specimen  
Other  (e.g.  obscuring  blood,  clotting  artefact)  
Benign   0 3   Clinical  follow-­up  
Consistent  with  a  benign  follicular  nodule  (e.g.  adenomatoid  
nodule,  colloid  nodule)  
Consistent  with  lymphocytic  (Hashimoto)  thyroiditis  in  the  proper  
clinical  context  
Consistent  with  granulomatous  (subacute)  thyroiditis  
Other  
Atypia  of  Undetermined  Significance  or  Follicular  Lesion  of  
Undetermined  Significance  
5 15   New  biopsy  
Follicular  Neoplasm  or  Suspicious  for  a  Follicular  Neoplasm   15 30   Surgical  lobectomy  
No  frozen  section  
recommended  Specify  if  Hürtle  cell  (oncocytic)  type  
Suspicious  for  Malignancy   60 75   Surgical  lobectomy/  
thyroidectomy  
Frozen  sections  may  help  
during  the  surgery  
  
  
Suspicious  for  papillary  carcinoma  
Suspicious  for  medullary  carcinoma  
Suspicious  for  metastatic  carcinoma  
Suspicious  for  lymphoma  
Other  
Malignant   97 99   Thyroidectomy  
Papillary  thyroid  carcinoma  
Poorly  differentiated  carcinoma  
Medullary  thyroid  carcinoma  
Undifferentiated  (anaplastic)  carcinoma  
Squamous  cell  carcinoma  




Table 5. $e Bethesda System for Reporting $yroid Cytopathology (79).
suspected follicular neoplasia, a primary lobectomy is performed (80). If a diagnosis of 
FTC at histology is made, a complementary thyroidectomy will be performed. If a single 
occult papillary microcarcinoma without lymph node metastasis is incidentally found, a 
lobectomy may be considered su)cient treatment (80). A primary total thyroidectomy 
will be performed if malignancy is evidenced in FNAB; in a suspected malignancy a frozen 
section will be performed during surgery for veri!cation of a malignancy (21) (Table 5).
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$e extent of surgery is dependent on the spread of disease to the surrounding tissues. $e 
completeness of the surgical resection is important, because it de!nes the outcome of the 
disease (70). Due to growing morbidity in PTC, a lateral lymph node dissection of the neck 
is not commonly recommended if US imaging of lymph nodes of the neck is found negative. 
Most experts, on the other hand, routinely advocate a central dissection of at least the T3 or 
T4 primary lesions, because central lymph node metastases in the thyroid bed are common, 
their detection with US is uncertain and dissection improves staging accuracy and decision 
for radioiodine administration (81). Previously, it was believed that lymph node metastasis 
had no e#ect on prognosis, but this argument has been overruled in support of a more 
concise dissection of lymph nodes (81).
Following thyroidectomy, in approximately 4 weeks radioactive iodine ablation (I131) of 
1110+3700 MBq is performed for patients with PTC or FTC to destroy any remaining thyroid 
tissue and possible micrometastases, because normal thyroid cells and well-di#erentiated 
carcinoma cells also concentrate radioactive iodine (82). In Finland, I131 is administered 
for all WDFTC patients with a tumour above 1 cm in diameter or if disease is multifocal 
or metastases are present. I131 is not given to patients with PDTC or ATC, because these 
cancers seldom concentrate iodine due to disease dedi#erentiation. In PDTC, ablation 
may be considered if the disease progresses. Ablation is given under TSH stimulation by 
thyroxin deprivation or administration of rhTSH. Ablation is repeated if remnant thyroid 
tissue is evident 6+8 months a*er the !rst dose during routine follow-up, as discovered with 
gamma and US imaging and serum thyroglobulin measurement. $e thyroxin dose is kept 
high to suppress the trophic e#ect of TSH. Metastases and neck recurrences are treated, if 
possible, with secondary surgery. Other treatments for less di#erentiated and metastasized 
diseases include external radiation and chemotherapy which are o*en given both pre- and 
postoperatively. New treatments such as tyrosine kinase inhibitors have been studied (83).
$yroid carcinoma patients are monitored by yearly follow-up, including clinical 
examination, measurements of non-TSH-stimulated thyroglobulin, TSH and free thyroxin 
or T3 and US imaging of the neck (every 2 years) to ensure a disease-free state. If these 
examinations prove positive, gamma imaging with an 185+MBq dose and TSH-stimulated 
thyroglobulin measurement (including measurement of antithyroglobulin antibodies) will 
be pursued (21). Other imaging methods are also used if necessary, such as positron emission 
tomography (PET) using "uoro-18-deoxyglucose or CT. Follow-up should be lifelong, since 
recurrences may occur many years a*er initial therapy.
 
5.3     Tumorigenesis  and  genetics  of  follicular  thyroid  tumours
Genetic cancer susceptibility is more common among endocrine tumours than any other 
human neoplasia (2). Six percent of familial nonmedullary thyroid cancers (FNMTCs) are 
believed to be familial follicular thyroid cancers (FFTCs), although no diagnostic criteria 
have been established. FFTC may be associated with syndromes such as Cowden or Werner 
Review  of  the  Literature
29
syndromes or the Carney complex. Mutations in the phosphatase and tensin homologue 
(PTEN) tumoursuppressor gene cause the Cowden syndrome, with susceptibility to breast, 
endometrial, thyroid, kidney and colorectal cancers, including dermatologic, gastrointestinal 
and neurologic features. Up to 10% of patients with Cowden syndrome develop a thyroid 
cancer, usually an FTC. Werner syndrome, also known as adult progeria, caused by a 
mutation in the Werner syndrome, RecQ helicaselike (WRN) gene, causing premature 
aging in patients, is associated with an increased risk of cancer, including FTC. $e Carney 
complex, caused by mutations in protein kinase, cyclic adenosine monophosphate (cAMP)-
dependent, regulatory, type 1, alpha (PRKAR1A) gene or chromosome 2p16, includes 
neoplasias in the heart, skin, endocrine organs such as the thyroid, and pigmentations of the 
skin and endocrinopathy.
Tumorigenesis of FTC is a much-debated topic. Suggestions of de novo mutations in thyroid 
cells, forming a carcinoma, are common. $e most popular theory of classical multistep 
carcinogenesis suggests a precursor formation from an FTA, which acquires genetic alterations 
to give the tumour a growth-promoting and an invasive phenotype (Figure 3). However, 
these concepts are challenged, because the proliferation rate of adult thyrocytes is low, thus 
limiting the time for accumulation of genetic alterations. In contrast, during goitrogenesis 
an immense increase in thyroid cell number occurs, which leads to a burst of mutational 
events and a failure of mutation repair systems during the higher replication pace. However, 
the spontaneous mutation rate in the thyroid is much higher than in other organs of mice at 
least (55). Another point is the wide heterogeneity of thyroid carcinomas, which are unlikely 
to be caused by only one mutation, which may once again be argued because mutations may 
occur at any site of the pathway, leading to similar end-events. However, when the DNA 
copy number of follicular thyroid neoplasias was characterized, FTAs showed mainly gains 
in genetic material, whereas FTCs showed deletions, but identical alterations were also seen, 
agreeing with the classical multistep concept (84,85). Previous studies showed that goitre 
and benign adenomas were strong risk factors for thyroid cancer (18,22,86). A carcinoma 
arising within a goitrous thyroid gland is smaller and develops at an older age then in patients 
whose solitary carcinoma nodules arise de novo (87). Genetic studies propose a pattern of 
cumulative alterations in tumour progression. Furthermore, it has also been suggested that a 
minimally invasive FTC is a precursor to widely invasive FTC (88,89).
Follicular cell-derived neoplasias to have genetic alterations in at least two distinct 
intracellular signaling pathways, leading to uncontrolled growth: the MAP kinase 
pathway and the phosphatidylinositol-3-kinase-protein kinase B (PI3K-AKT) pathway. 
Up to 30+50% of FTCs, especially less-di#erentiated FTCs, harbour mutations of the 
latter pathway, such as gain-of-function point mutations in the RAS and PI3K genes and 
loss-of-function mutation in the PTEN, %-catenin and tumour protein 53 (TP53) genes. 
A progressive increase in the rate of RAS and PI3KCA mutations may be the common 
pathogenesis of FTAs transforming to FTCs and further to ATCs. A RAS mutation, which 
is the most common mutation in FTCs, is seen in 40+50% of conventional FTCs and in 
20+40% of conventional FTAs (23,58).
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A fusion gene of paired box gene 8-peroxisome proliferator-activated receptor ( (PAX8-
PPAR(), which causes loss of growth inhibitory control in the PPAR( gene, is seen in 30+50% 
of FTCs but also in 10% of FTAs (12). However, in FTCs it is associated with vasculoinvasion 
and metastatic disease (90-92). $e RAS and PPAR(-PAX8 mutations do not overlap, 
which suggests two distinct pathways of tumorigenesis. Lately, new factors have been found 
a#ecting the pathogenesis of FTC, called microRNAs (miRNAs), which are small noncoding 
segments of ribonucleic acid (RNA) important in negatively regulating gene transcription 
(93).
Neoplasias are composed of genetically heterogeneous cells, each with di#erent phenotypic 
characteristics and di#erent proliferative potentials. According to a new hypothesis, a small 
subset of cells called cancer stem cells (CSCs) plays a major role in carcinogenesis (85). $ese 
undi#erentiated and pluripotent cells originate from either normal stem cells through genetic 
alterations or from progenitor cells or adult normal cells via a dedi#erentiation process called 
the epithelial to mesenchymal transition (EMT) (97). $ese cells may rest as dormant cells, 
self-renew or produce a progenitor cell that di#erentiates into either a well-di#erentiated or 
an undi#erentiated cancer cell and eventually multiplies and forms the bulk of the tumour 
(98). Dormant and quiescent CSCs without active growth signalling are inert to traditional 
treatments, because these treatments are directed against rapidly dividing cells (99).
CSCs have been isolated from PTC, FTC and ATC (100). In normal thyroid tissue only 0.1% 
of cells are evidenced as stem cells, while 1+2% are in goitrous tissue (99). CSCs with di#erent 
potentials for proliferating may explain the thyroid tumorigenesis in di#erent carcinoma 
subtypes (98,101). Fetal CSCs without any markers of di#erentiation are believed to give rise 
to ATC, while thyroblasts with both fetal and di#erentiation markers give rise to PTC and 
prothyrocytes with di#erentiation markers but without fetal markers give rise to FTC (101). 
Immatureness of the CSC population, may be linked with the degree of cancer malignancy; in 
ATC the stronger the expression of cluster of di#erentiation 133 (CD133), a stem cell marker, 
the stronger is the ability of carcinoma to initiate tumours compared with low expression (101).
Figure 3. Tumorigenesis of thyroid neoplasias. Modi!ed from (11,59,94-96).
Review  of  the  Literature
31
5.4   Tumour  markers  of  follicular  thyroid  neoplasias
Hanahan and Weinberg (102) listed nine hallmarks of cancer to understand the complex 
process of human neoplasia. $e most constitutive hallmark is the ability to constantly 
proliferate. Proliferation is activated by growth factors in an autocrine manner or by disrupting 
self-attenuating signalling, which is carefully controlled in normal cells. $e remaining 
hallmarks include evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, activating invasion and metastasis, in"ammation, 
reprogramming of energy metabolism and evading immune destruction. Carcinogenesis is 
believed to proceed as a sequential accumulation of alterations in genes such as oncogenes, 
growth suppressor genes, growth factors and growth factor receptor genes involved in these 
processes, leading to a colony of genetically modi!ed tumour cells with a growth advantage 
over normal cells. Several immunohistochemical protein markers indicating these hallmarks 
have been studied in the !eld of thyroid neoplasia (Figure 4, Table 6).
Figure 4. Hallmarks of cancer by Hanahan and Weinberg (102). Markers studied are next to the hallmarks in 
question.
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Marker   Role   FTA   WDFTC   PDFTC   Ref  
MIB-­1   Detection  of  highly  proliferative  tumours   <5%  positive  cells   5-­10%  positive  cells   10-­30%  positive  cells   (103-­105)  
TPO   Confirming  thyroid  origin  of  tissue   Positive   Positive   Focal  positivity   (106,107)  
TTF-­1   Confirming  thyroid  origin  of  tissue   Positive   Positive   Focal  positivity   (106,108,109)  
RAS  mutation   Dedifferentiation,  aggressive  behaviour   Positive   Positive   Often  positive   (23,58,96,110,111)  
PAX8-­PPAR    Carcinogenesis,  vascular  invasion   Atypical  FTAs  positive   Positive   Rarely  positive   (90,111,112)  
Cyclin  D1   Carcinogenesis,  metastasis   Low  positivity   Intermediate  positivity   High  positivity   (113)  
ER    Tumorigenesis,  aggressive  behaviour   Low  positivity   Intermediate  positivity   High  positivity   (114-­117)  
ER    Tumorigenesis,  aggressive  behaviour   Positive   Intermediate  positivity   Low  positivity   (114-­118)  
p27   Dedifferentiation,  poor  prognosis   Positive   Intermediate  positivity   Negative   (103,105,113,119)  
p53   Dedifferentiation,  aggressive  behaviour   Negative   Negative   20-­30%  positive  cells   (95,96,103,112,120,121)  
Telomerase   Tumour  development,  aggressive  behaviour   Negative   Intermediate  positivity   High  positivity   (112,122)  
Galectin-­3   Tumour  progression,  metastasis   Negative   Intermediate  positivity   High  positivity   (53,106,119,123)  
E-­cadherin   Invasiveness,  poor  prognosis   Positive   Intermediate  positivity   Negative   (124,125)  
-­catenin   Dedifferentiation,  aggressive  behaviour,  poor  prognosis   Positive   Intermediate  positivity   Negative   (106,112)  
Cytokeratin-­19   Identification  of  PTC   Focal  positivity   Intermediate  positivity   Low  positivity   (106,123,126)  
HBME-­1   Carcinogenesis,  metastasis   Low  positivity   Positive   Positive   (53,106,127)  
TGF   Tumorigenesis   Positive   Intermediate  positivity   Low  positivity   (128)  
IMP-­3   Tumorigenesis,  metastasis,  poor  prognosis   Negative   Positive   Positive   (129,130)  
COX-­2   Tumorigenesis   Low  positivity   Intermediate  positivity   High  positivity   (106,131)  
VEGF   Tumorigenesis,  metastasis,  poor  prognosis   Low  positivity   Intermediate  positivity   Positive   (127,132)  
EGF   Tumorigenesis,  aggressive  behaviour   Low  positivity   Intermediate  positivity   Positive   (96,132,133)  
MMP   Invasion,  metastasis   Low  positivity   Intermediate  positivity   Positive   (127,134)  
  
Table 6. Some markers studied in follicular thyroid neoplasia
5.4.1 Ability to proliferate
$e growth activity of thyroid tumour cells is inversely correlated with the di#erentiation 
level of carcinomas (135). $e proliferation indexes (PIs) of MIB-1 antibody (Ki-67 
antigen) are 1+5%, 5+10%, 10+30% and >30% in the spot areas of WDTC, PDTC and ATC, 
respectively. MIB-1 is an essential tool in clinical pathology, indicating the proliferative 
ability of the tumour.  It has prognostic and predictive value and is more commonly used in 
the diagnostics of PDTCs and ATCs (103-105,113,136).
TPO is commonly used in clinical diagnostics to con!rm tissue, as it is a thyroid-speci!c 
enzyme involved in the synthesis of thyroid hormone and expressed solely in thyroid 
tissue. Its expression is focally lost in PDTCs, but it is mainly present in well-di#erentiated 
carcinomas, adenomas and normal thyroid tissue. $us, the absence of TPO indicates loss of 
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Marker   Role   FTA   WDFTC   PDFTC   Ref  
MIB-­1   Detection  of  highly  proliferative  tumours   <5%  positive  cells   5-­10%  positive  cells   10-­30%  positive  cells   (103-­105)  
TPO   Confirming  thyroid  origin  of  tissue   Positive   Positive   Focal  positivity   (106,107)  
TTF-­1   Confirming  thyroid  origin  of  tissue   Positive   Positive   Focal  positivity   (106,108,109)  
RAS  mutation   Dedifferentiation,  aggressive  behaviour   Positive   Positive   Often  positive   (23,58,96,110,111)  
PAX8-­PPAR    Carcinogenesis,  vascular  invasion   Atypical  FTAs  positive   Positive   Rarely  positive   (90,111,112)  
Cyclin  D1   Carcinogenesis,  metastasis   Low  positivity   Intermediate  positivity   High  positivity   (113)  
ER    Tumorigenesis,  aggressive  behaviour   Low  positivity   Intermediate  positivity   High  positivity   (114-­117)  
ER    Tumorigenesis,  aggressive  behaviour   Positive   Intermediate  positivity   Low  positivity   (114-­118)  
p27   Dedifferentiation,  poor  prognosis   Positive   Intermediate  positivity   Negative   (103,105,113,119)  
p53   Dedifferentiation,  aggressive  behaviour   Negative   Negative   20-­30%  positive  cells   (95,96,103,112,120,121)  
Telomerase   Tumour  development,  aggressive  behaviour   Negative   Intermediate  positivity   High  positivity   (112,122)  
Galectin-­3   Tumour  progression,  metastasis   Negative   Intermediate  positivity   High  positivity   (53,106,119,123)  
E-­cadherin   Invasiveness,  poor  prognosis   Positive   Intermediate  positivity   Negative   (124,125)  
-­catenin   Dedifferentiation,  aggressive  behaviour,  poor  prognosis   Positive   Intermediate  positivity   Negative   (106,112)  
Cytokeratin-­19   Identification  of  PTC   Focal  positivity   Intermediate  positivity   Low  positivity   (106,123,126)  
HBME-­1   Carcinogenesis,  metastasis   Low  positivity   Positive   Positive   (53,106,127)  
TGF   Tumorigenesis   Positive   Intermediate  positivity   Low  positivity   (128)  
IMP-­3   Tumorigenesis,  metastasis,  poor  prognosis   Negative   Positive   Positive   (129,130)  
COX-­2   Tumorigenesis   Low  positivity   Intermediate  positivity   High  positivity   (106,131)  
VEGF   Tumorigenesis,  metastasis,  poor  prognosis   Low  positivity   Intermediate  positivity   Positive   (127,132)  
EGF   Tumorigenesis,  aggressive  behaviour   Low  positivity   Intermediate  positivity   Positive   (96,132,133)  
MMP   Invasion,  metastasis   Low  positivity   Intermediate  positivity   Positive   (127,134)  
  
di#erentiation of tumour cells. It has predictive value of the e#ectiveness of the treatment as 
radioiodine uptake is poor if the expression of TPO is low (106,107). $yroid transcription 
factor -1 (TTF-1) is also a protein expressed in the thyroid. It is also found in the brain, 
lungs and MTC. It is commonly used in clinical practice in the same purpose as TPO. TTF-1 
expression is similarily lost in PDTC and ATC (106,108,109).
$yroglobulin detection is made both from serum and histologic sample. Serum level is a 
well-acknowledged marker predicting poor survival (137), whereas immunohistochemical 
staining is performed to con!rm the origin of tissue similarly as TPO and TTF-1. 
Measurement of repeated serum thyroglobulin level predicts the long-term outcome of 
di#erentiated thyroid cancer patients (138).
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5.4.2 Enabling replicative immortality
A genetic mutation in oncogenes generate uncontrolled growth signals and cause cancer 
cells to develop and proliferate. Several oncogenes have been studied in thyroid cancer. In 
follicular neoplasias, the main alterations are in RAS and PAX8 genes. On the contrary, BRAF 
and RET/PTC mutations are speci!c to PTC (58). Activating point mutations in RAS genes 
(H-RAS, K-RAS, N-RAS), encoding intracellular G-proteins, involved in signal transmitting 
in MAP and PI3K-AKT pathways, are absent from non-neoplastic thyroid lesions. $ey 
are mainly seen in follicular neoplasias and only rarely in PTC. Virtually all PTCs positive 
are follicular variants (23,58,110). RAS mutations are linked to iodine de!ciency and are 
thought to represent an early event in thyroid tumorigenesis. Futhermore, RAS mutations 
are correlated with the traits of dedi#erentiation traits, such as diminishing thyroglobulin 
expression and aggressive behaviour (96,111,112). Carcinomas with RAS mutation are shown 
to metastasize more o*en than carcinomas without RAS mutations (58).
Paired box gene 8 (PAX8) encodes a transcription factor involved in the regulation of cell 
cycle, DNA repair, metabolism, replication and cell polarity. Its protein expression is shown 
to be decreased or lost in FTC (90). PPAR( is a tumour suppressor gene which stimulates 
lipogenesis, promotes di#erentiation and inhibits cell proliferation. A fusion gene PAX8-
PPAR(, arises from translocation t(2;3)(q13;p25) and leads to suppression of the function 
of PPAR( gene (90). It is seen in FTCs, FTAs and FVPTCs, but not in conventional PTCs. 
FTAs with PAX8-PPAR( translocation might be precursors for FTCs since this mutation 
was seen in a small group of FTAs, which evidently show atypical features. FTCs harbouring 
PAX8-PPAR( translocation are smaller in size, present at younger age and are more 
vasculoinvasive, whereas FTCs harbouring RAS mutations are larger and present at older 
age (111). Interestingly these two genetic alterations are rarely seen in Hürtle cell neoplasias, 
which are thought to represent a distinct type of thyroid neoplasia.
Nikiforova et al have suggested the use of these two distinct molecular markers in FNAB 
diagnostics: RAS as a neoplasia marker and PAX8-PPAR( as a malignancy marker (111), 
although opposing opinions have also been presented (60). $e American $yroid 
Association (ATA) recommends the use of molecular markers such as BRAF, RET/PTC, 
RAS, and PAX8-PPAR(, in evaluating the thyroid nodules with undetermined cytology (70).
Cell cycle related genes include promoters, such as Cyclin D and E and inhibitors, such 
as p27, p53 and retinoblastoma (RB) protein. $e promoters are considered oncogenes 
and the inhibitors tumour suppressor genes. $e most studied promoter of the cell cycle is 
Cyclin D1, encoded by human CCND1 gene, which is one of the most frequently ampli!ed 
genes in human cancers. It is a key regulator of the G1/S transition through the cell cycle by 
inactivating RB protein. Cyclin D1 is increased just before the S phase in normal cells, while 
in neoplastic cells it is highly overexpessed. In thyroid, it is commonly mildly expressed in 
well-di#erentiated carcinomas, intermediately in poorly di#erentiated and highly expressed 
in metastatic PTC and ATC (65,113). It was expressed stronger in FTC than in FTA in one 
study (113), although the result could not be repeated (139).
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Hormones and hormone receptors, especially estrogens, are a much-studied topic in thyroid 
cancer as thyroid diseases are o*en connected to female gender. Estrogen receptor subtypes 
& and % are involved in cancer cell proliferation and are thought to oppose one another´s 
action: & induces proliferation, whereas % suppresses it (140). According to previous studies 
ER% is a tumour suppressor inhibiting cell´s dedi#erentiation maintaining the cell in its 
primary phenotype. $e prognostic association with ER% has also reported in breast cancer, 
ovarian cancer, and lung cancer (141-143). Both & and % subtypes are expressed in normal 
as well as neoplastic thyroid tissue. $e expression of & receptor has shown both higher and 
lower expression intensities in carcinoma tissue compared to non-neoplastic thyroid tissue 
(114,115,144). On the other hand, % receptor is expressed stronger in FTC than in FTA 
(114), although contradictory results have been published (115), as well as results with no 
di#erence (116,118).
5.4.3 Evading growth suppressors
Tumour suppressor genes suppress the action of oncogenes. A mutation in these recessive 
genes cause loss of the suppressive action through a phenomenon called loss of heterozygosity 
(LOH). LOH in tumour suppressor genes is more o*en seen in FTC than in PTC (96).
$e cyclin dependent kinases (CDK), which facilitate the progression of the cell cycle, are 
activated by cyclins and inhibited by CDK inhibitors such as  protein 27 (p27). P27 inhibits 
the cell cycle by activating RB protein, a#ecting the same phase in the cell cycle as Cyclin D1. 
P27 is shown to be downregulated in thyroid cancer, especially in PTC, and maybe helpful 
in di#erential diagnostics of follicular neoplasias. It has also shown prognostic value when 
comparing WDTC to PDTC (103,105,113,119).
5.4.4 Resisting cell death
$e tumour-suppressor gene TP53 is de!ned as “the guardian of the genome” with a main 
function to arrest the cell cycle in G1 phase in the occurrence of DNA damage enabling the 
repair mechanisms to correct the damage. In the case of failed repair, the cell would proceed 
to apoptosis activated by protein 53 (p53). Conversely, loss-of-function mutation of the 
TP53 gene leads to resistance of cell death inducing genomic instability, prolonged cell life 
and cancer progression. Overexpression of mutated p53 is seen abundantly in ATC and in 
lower amounts in PDTCs, while it is nearly absent in WDTCs thus supporting the classical 
theory of dedi#erentiation process from a WDTC to PDTC and eventually to ATC (135). 
Overexpression of p53 is a marker for those tumours with an ability to behave aggressively 
as well as an independent prognostic factor for overall survival of patients with thyroid 
carcinoma (65,95,96,103,120,121).
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Telomeres are thought to be the molecular clock for ageing of human cells. $ese end parts 
of the chromosomes are shortened during every cell cycle and eventually run out, which 
activates cell apoptosis. Telomerase enzyme is responsible for maintaining the length of 
telomeres in the ends of chromosomes. Activity of the telomerase enzyme is shown in a 
majority of all types of human cancer (80-90%). Normal thyroid tissue is shown to lack 
telomerase activity, whereas in malignant cells it is upregulated, especially in PDTC. It 
may be a marker of aggressiveness and involved in the progression from WDTC to PDTC 
(112,122).
MicroRNAs (miRNAs) are small non-coding RNA molecules that can modulate gene 
expression by binding to the target messenger RNA, which can result in the decreased 
expression of the target protein. Recent evidence has shown that these molecules are involved 
in initiation and progression of several types of cancer. In thyroid cancer some miRNAs 
(miR-7 and miR-200b) are shown to be exclusive for FTC (145).
5.4.5 Activating invasion and metastasis
Altered adhesion molecules correlate with tumour progression, especially invasiveness and 
metastatic potential. Expression of such molecules is lost in widely invasive and metastatic 
thyroid carcinomas. Galectin-3, a member of the adhesion molecules called lectins, plays 
an important role in cell-cell/matrix interactions, adhesion, migration and repairing of 
damaged cells. It is expressed in WDTCs, especially in PTC and less intensely in FTC, but 
it is absent or weakly expressed in adenomas and non-neoplastic thyroid tissue. PDTC 
and ATC strongly express galectin-3. It may help in the di#erentiation between minimally 
invasive FTC and FTA (53,106,119,123).
$e expression of e-cadherin, a transmembrane glycoprotein adhesion molecule essential for 
maintaining intercellular junctions, is shown to be lower in widely invasive and metastatic 
compared to minimally invasive FTCs. It is correlated with poor prognosis of thyroid 
cancer (124,125). Membranous expression of %-catenin, an adhesion molecule connected 
to e-cadherin, is lost in PDTC and ATC indicating loss of di#erentiation. It is connected to 
poor prognosis, as well (106,112).
Cytokeratin-19 (CK-19) is a low molecular weight cytokeratin !lament responsible for 
the structural integrity of epithelial cells. It is highly expressed in PTC and only weakly or 
focally in FTC, mainly in the oncocytic variant. $e expression of CK-19 is weak and focal in 
FTAs and negative in normal thyroid tissue. Some focal staining may appear near areas with 
chronic in"ammation. CK-19 is commonly used in clinical diagnostics of thyroid nodules to 
identify conventional or FVPTC (106,123,126,146).
Hector Battifora Mesothelial cell (HBME-1), is an antibody targeted to microvilli on the 
surface of mesothelial cells. It is expressed strongly in PTCs and FTCs and weakly in FTAs. 
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It is absent or weakly positive in non-neoplastic thyroid tissue, such as nodular goitre or 
normal thyroid tissue, proposing a position as a neoplasia marker. Futhermore, upregulated 
expression of HBME-1 correlates with metastasis of thyroid cancer (53,106,127).
Transforming growth factor % (TGF%) is an inhibitory growth factor that is involved in 
cell growth, di#erentiation and apoptosis. It causes an arrest in the G1 phase of the cell 
cycle. Resistance to TGF-mediated cell growth inhibition is a well-known pathogenesis in 
epithelial neoplasia. TGF receptor (TGFR) expression is shown to be reduced in minimally 
invasive FTCs compared to FTAs  (128).
A new marker called insulin-like growth factor mRNA binding protein 3 (IMP-3), 
involved in cell proliferation and growth, has shown potential as a neoplasia marker. It is 
overexpressed in follicular-patterned thyroid carcinomas (FTC, FVPTC) and negative in 
benign thyroid tumours and normal thyroid tissue (129).  In PDTCs, it is shown to have 
prognostic signi!cance, correlating with distal and nodal metastatic disease and poorer 
overall survival (130).
5.4.6 Inducing angiogenesis
Cyclo-oxygenase 2 (COX-2) is involved in the synthesis of prostaglandins. It is also involved 
in tumorigenesis by promoting angiogenesis and inhibiting apoptosis. It is shown to be 
absent in normal thyroid tissue and hyperplastic nodules, but is expressed in FTA, PTC 
and FTC and thyroiditis (106). COX-2 expression is associated with poor prognosis in FTC 
(131), and in PTC (147).
Vascular endothelial growth factor (VEGF) stimulates migration and proliferation of 
endothelial vessels and promotes angiogenesis and vascular growth. In WDTC, increased 
VEGF expression is associated with metastasis and poor prognosis (127,132).
Epidermal growth factor (EGF) regulates cell growth, proliferation and angiogenesis. 
In addition, it opposes di#erentiation, by inhibiting thyroglobulin expression and iodide 
uptake. RAS-RAF-MEK-ERK and the AKT-PI3K pathways are known to be activated by 
EGFR. $e amount of EGF receptors  is increased in malignant thyroid tissue, especially in 
PDTCs and ATCs, which indicates a loss of TSH-dependency and inability to respond to 
radioiodine therapy (96,132,133). EGF is shown to activate invasion in FTC, by activating 
matrix metalloproteinase-9 (148).
Matrix metalloproteinases (MMP) participate in degrading extracellular matrix and are 
involved in tumour invasion and angiogenesis. MMP-1, -2 and -9 are shown to correlate 
with metastases in FTC (127,134).
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5.4.7  Reprogramming of energy metabolism
Cancer cells use aerobic glycolysis (Warburg e#ect) for cell growth and survival. A link 
between sustained aerobic glycolysis and activation of oncogenes or loss of tumour suppressor 
genes is established (149). Speci!c changes in metabolic systems are linked to cancer. For 
example, mutations in fumarate hydratase correlate to kidney cancer and leimyomatosis, 
and mutations in succinate dehydrogenase to pheochromocytomas and paragangliomas. 
Mutated RAS gene, a gene involved in FTC carcinogenesis, is linked to enhanced glycolysis. 
Also mutations in PI3K, PTEN and TP53 genes, seen also in thyroid cancer, are linked to 
altered metabolism leading to increased metabolic function of cancer cells (149).
5.4.8  In"ammation and evading immune destruction
In"ammation has long been known to a#ect neoplastic lesions in an antagonizing way through 
innate immune cells (natural killer cells, cytotoxic T lymphocytes). On the other hand, 
chronic in"ammation is shown to have tumour-enhancing e#ect. Chronic in"ammation 
caused by microbes or various carcinogens is thought to initiate carcinogenesis rather 
than promote it. Interestingly, up to 15 to 20% of cancer cases worldwide are thought to be 
initiated by infections. Infection induces in"ammation releasing e.g. reactive oxygen radicals 
which in"ict genetic alterations and promote cancer formation (150,151). $e association 
between in"ammation and carcinogenesis has been demonstrated with Helicobacter pylori 
infection and stomach cancer (152), ulcerative colitis/ Crohn´s disease and colon cancer 
(153), human papilloma virus infection and cervical cancer (154), hepatitis C infection and 
liver cancer (155), as well as thyroiditis and thyroid cancer (156). On the other hand the 
presence of protecting immune cells, such as lymphocytes and dendritic cells, are connected 
to better survival (157).
Rearrangement of RET/PTC may link PTC and in"ammation together. Activation of RET 
is shown in Hashimoto´s thyroiditis, which is a known risk factor for PTC (158-160). 
Interestingly, the oncogenic pathway of RAS gene and chronic in"ammation are shown to 
cause tumour formation in a positive feedback manner (158,161). PI3K and MAPK pathways 
are also activated in thyroid carcinogenesis. $ey are also important in in"ammation through 
activating chemokine receptors and promoting leukocyte migration (162).
$e area adjacent to the tumour, where the in"ammation o*en resides, is called the tumour 
microenvironment (“niche”). It contains multiple signals that enable the hallmarks of cancer 
to prevail. $ese chemotactic signals and growth factors a#ect cancer cells triggering EMT 
which is important in creating and maintaining CSCs, but also promotes tumour growth 
(EGF), angiogenesis (VEGF) and metastasis (MMPs). Tumours are portrayed as wounds 
that never heal, where tissue injury promotes cell proliferation and regeneration with the aid 
of in"ammation but without a self-limiting trait (150,163).
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Part of the immune system, such as natural killer cells or macrophages, acts to resist tumour 
formation and eliminates incipient cancer cells. Tumours able to evade this surveillance 
have managed to avoid the immunological recognition and the elimination of tumour 
cells, by being only weakly immunogenic or by inducing in"ammation itself and recruiting 
own tumour-promoting cells of immune system, such as tumour-associated macrophages 
(TAMs). TAMs suppress the function of other immune cells thus securing tumour 
growth. Oncogene activation is shown to promote the formation of a tumour-promoting 
in"ammation enhancing and improving the environment for tumour progression (151). On 
the other hand presence of immune cells in tumours, such as lymphocytes and dendritic 
cells, is connected to better survival. $is may be explained by the tumour dormancy, i.e. 
tumour cells are inactive, but are activated if the surveillance of immune system is broken. 
$is is exempli!ed with immuno-compromised individuals who o*en su#er from increasing 
occurrence of cancer formation due to loss of immune surveillance (102,164).
Transcription factor NF-'B, involved in innate immunity and in"ammation, is activated 
by microbes, tissue damage, in"ammatory cytokines and genetic alterations. It activates via 
toll-like receptors, which induce the TLR-MyD88 signaling pathway and eventually activate 
in"ammatory mediators such as cytokines, adhesion molecules, proteases, angiogenic and 
antiapoptotic factors in order to promote cell survival. Indeed NF-'B is connected to tumour 
initiation and progression in association with in"ammation (158).
Toll-like receptors are a family of transmembrane receptors that recognize conserved 
molecular patterns of microbial origin (pathogen associated molecular pattern, PAMP) but 
also endogenous ligands. $ey control the host defence from infection and are part of the 
!rst line defence mechanism by recruiting and stimulating both adaptive and innate immune 
responses. TLRs also have a role in tissue repair and tissue injury-involved in"ammation by 
providing pro-survival and anti-apoptotic signals. $ey are shown to stimulate tumour cell 
proliferation and enhance survival (165). On the other hand, they also show an anti-tumour 
e#ect. For example TLR-7 and TLR-8 ligand, a drug called imiquimod, which is used to treat 
skin cancer (166) or TLR-9 ligand CpG is used to treat brain (167) and renal cancer (168). 
$us the TLR system is considered a double-edged sword in cancer (169).
TLR-3, a receptor o*en seen in dendritic cells directed against viral antigens, is shown to be 
overexpressed in PTC cells, but not in FTC cells. It is associated with enhancing in"ammatory 
reaction and cell growth in PTC (170). TLR-4, directed against lipopolysaccharides (LPS) 
of bacteria and viruses, is expressed in thyroid cells and it stimulates iodine uptake and 
thyroglobulin expression in them (171).
Cytokines, important mediators of in"ammation produced by immune cells, are involved in 
activation, growth and di#erentiation of target cells, several of them having proin"ammatory 
e#ects. In a study by Linkov et al (172) serum cytokines interleukin 8 (IL-8), hepatocyte 
growth factor (HGF), monocyte-induced interferon gamma (MIG), and IL-12p40 showed 
signi!cant accuracy in di#erentiating between benign and malignant thyroid tumours. In 
another study, expression of cytokine CRCX4, stimulated by nitride oxide, was connected to 
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lymph node metastasis in PTC (173). A chemokine CCL21 activating chemokine receptor 
7 stimulates tissue invasion and cell proliferation promoting thyroid carcinoma growth and 
lymph node metastasis (174).
Other mediators of in"ammation have been detected in thyroid carcinomas such as 
previously mentioned TAMs (positive for CD68), which are shown to be abundant in PDTCs 
and ATCs compared to WDTCs. TAMs are correlated with capsular invasion, extrathyroidal 
extension and decreased cancer-related survival suggesting that TAMs may promote tumour 
progression (175).
Several tissue markers have been studied in follicular thyroid neoplasias to aid in the 
problematic !eld of their di#erential diagnostics. However, further studies are needed 
to identify clinically relevant immunohistochemical markers of neoplasia, markers of 
malignancy and markers of aggressiveness in FTC. $e di#erentiation between a non-
neoplastic and a neoplastic thyroid lesion is important, because recommended management 
of neoplastic thyroid lesions is surgery, whereas non-neoplastic lesions need only to be kept 
under surveillance. Understanding the path of thyroid carcinogenesis, helps to !nd markers 
for di#erentiating between benign and malignant thyroid lesions. Although FTC o*en acts 
indolently, it is important to distinguish those patients with an aggressive disease as early 
as possible to direct them to a more thorough management.  $e focus of my studies was 
pointed towards speci!c markers: MIB-1, Cyclin D1, p53, TLR-2, TLR-4, CD45, estrogen 
receptor alpha (ER&), ER%, and a novel stem cell marker human embryonic stem cell 5 
(HES5). I investigated their clinical utility in follicular thyroid neoplasias.
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6     AIMS
$e speci!c aims were:
 
1) to re-evaluate and study the role of demogra!c and histopathological features of  
 FTCs on clinical outcome
2) to study the incidence of PDFTC in the HUCH region
3) to identify immunohistochemical
• markers of neoplasia
• markers of malignancy
• markers of aggressiveness in FTC
• prognostic markers of FTC
Aims
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7     MATERIALS  AND  METHODS
7.1     Patient  material
Follicular neoplasias were identi!ed from the database of the Department of Pathology, 
HUCH (QPati database) from a time period between 1990 and 2009. In all, 398 follicular 
neoplasias were found, including 354 FTAs and 44 FTCs. Out of all follicular neoplasias, 
all FTCs were selected (n = 44), and atypical (n = 9) and oxyphilic (n = 29) adenomas were 
selected. A group of consecutive cases of typical FTAs (n=45) was selected. A total of 83 
adenomas and thus 127 follicular neoplasias were included in the study. Futhermore, a non-
neoplastic control tissue group of 86 specimens were selected, including 23 normal thyroid 
tissue samples, 41 nodular goitre samples and 22 hyperplastic thyroid tissue samples from 
patients with hyperthyroidism.
$e total number of FTCs decreased by one from 44 patients, because the tissue material ran 
out (II, III). $e staining of one FTA specimen failed during the study, decreasing the total 
number to 82 (III). In study I, the number of patients was smaller, consisting of 90 patients 
(39 carcinomas, 51 adenomas) from 1990 to 2006 with follow-up until March 2010.
7.2     Clinical  data
Clinical data with follow-up extending until March 2011 was collected from patient records 
of the Department of Surgery and Oncology, Helsinki University Central Hospital (HUCH), 
survival data from the Population Register Center and cause of death from the patient records 
and from Statistics Finland. Collected patient data included age at the time of diagnosis, 
gender, symptoms prior to diagnosis, previous thyroid diseases, FNAB results if taken, TNM 
staging, surgery type (lobectomy or total thyreoidectomy), surgical complications, radioiodine 
treatments, administration of additional treatments (external radiation, chemotherapy and 
additional surgical treatments), recurrencies and secondary metastasis.
All FTCs diagnosed in HUCH region were gathered from a time period of 20 years from 
1990 until 2009 (range 0-6 patients per year). Mean follow-up time for all FTC patients was 
9.0 years. A mean survival time for all deceased patients (n=8) was 5.4 years, for PDFTC 
patients 4.7 years and for WDFTC patients 6.1 years. Altogether 83 adenomas were gathered 
as well as 86 non-neoplastic consecutive thyroid tissues. During follow-up, none of the 
adenoma patients developed thyroid cancer. Characteristics of study patients are shown in 
Table 7.
All study patients underwent thyroid surgery at the Department of Surgery, HUCH. $yroid 
surgery was performed a*er a cytology report of a suspicion of a thyroid neoplasia (follicular 
neoplasia, oncocytic cells, suspicion of a PTC) to 30 of 44 (68%) patients with FTC, to 55 
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Table 7. Clinical characteristics of study material.
  
   All   Women   Men  
Gender  
ratio  
FTCs   44   24   20   1.2:1  
Mean  age  (range)   58  yrs  (24-­83  yrs)   59  yrs  (24-­80  yrs)   56yrs    (40-­83  yrs)     
Mean  size  (range)   4.6  cm  (0.6-­14  cm)   4.5  cm  (0.6-­10  cm)   4.7  cm  (1.2-­14  cm)     
FTAs   83   66   17   3.9:1  
Mean  age  (range)   49  yrs  (19-­79  yrs)   49  yrs  (21-­79  yrs)   48  yrs  (19-­69  yrs)     
Mean  size  (range)   2,5  cm  (0.2-­7  cm)   2.6  cm  (0.2-­7  cm)   2.1  cm  (0.5-­6  cm)     
Non-­neoplasias   86   57   29   2.0:1  
Mean  age  (range)   50  yrs  (16-­87  yrs)   47  yrs  (18-­87  yrs)   55  yrs  (16-­83  yrs)     
Normal  thyroid  tissue   23   16   7   2.3:1  
Mean  age  (range)   41  yrs  (19-­63  yrs)   41  yrs  (18-­63  yrs)   42  yrs  (29-­59  yrs)     
Hyperplastic  thyroid  tissue   22   15   7   2.1:1  
Mean  age  (range)   41  yrs  (16-­78  yrs)   39  yrs  (25-­60  yrs)   46  yrs  (16-­78  yrs)     
Goitrous  thyroid  tissue   41   26   15   1.7:1  
Mean  age  (range)   60  yrs  (25-­87  yrs)   56  yrs  (25-­87  yrs)   65  yrs  (42-­83  yrs)     
of 83 (66%) patients with FTA. Surgery was performed due to an enlarged thyroid gland 
with cytology report indicating a goitrous lesion to 6 (14%) patients with FTC and to 16 
(19%) patients with FTA. FNAB was skipped and primary surgery was proceeded due to a 
suspected large symptomatic goitre in 4 (9%) of FTC patients, in 9 (11%) of FTA patients; 
due to a suspected malignant disease (evident metastasis or widely invasive tumour to the 
surrounding tissues prior to surgery) in 4 (9%) of FTC patients; or due to hyperparathyreosis 
in 3 (4%) of FTA patients.
Lobectomy was performed in 30 of 44 (68%) FTC patients because suspicion of a malignancy 
was not evident in FNAB. In three (7%) patients a subtotal resection was done (istmectomy 
for one patient, resection of cervical lymph nodes for two patients). In all these 33 patients 
(75%) a completing thyroidectomy was performed a*er veri!cation of a FTC at histology. 
Primary total thyroidectomy was performed in 11 (25%) FTC patients because of apparent 
metastases at the time (5 patients, 45%), a discovery of a grossly invasive growth of the 
tumour during operation (4 patients, 36%) or large multinodular thyroid with pressure 
symptoms (2 patients, 18%). Seven patients su#ered from surgical complications: six from 
laryngeal nerve palsy and one from a hematoma of the neck.
All carcinoma patients received 30 – 120 mCi (1110 – 4440 MBq) radioiodine ablation 
(131I) within approximately 4 – 6 weeks a*er thyroidectomy, excluding one patient who 
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died 24 days a*er primary operation. Patients with advanced disease (n = 14, 32%) received 
additional radioiodine treatment, radiation, surgery or chemotherapy. All patients were 
followed until the end of March 2010, none were lost to follow-up.
7.3     Incidence  data  on  thyroid  cancer
Data concerning thyroid cancer incidence from 1970 until 2004 was received from Finnish 
Cancer Registry from courtesy of Professor Risto Sankila, M.D. $is data, presented in study 
I, included incidence numbers as well as numbers of new cases group according to histology 
and gender in Finland.
7.4     Preparation  of  archived  tissue  material
$e archival tumours were initially !xated into formalin in order to preserve the structure 
of the tissue and stop metabolism of the cells. Para)n embedding was performed, a*er 
washing and dehydration with ascending series of alcohol solutions and diluting in an 
organic solvent, in order to harden the tissue to be cut into thin slides with a microtome. 
Archived para)n blocks were cut with a microtome and para)n was dissolved with a solvent 
and rehydrated with descending alcohol series. Haematoxylin stain was performed in water 
and counterstained with eosin in alcohol a*er dehydration. Finally, the stained slides were 
mounted with a non-aqueous medium and a coverslip. Haematoxylin stains the cytoplasm 
of the cell into pinkish colour whereas eosin stains nuclei as blue (HE stain) (176).
7.5     Re-­evalution  of  histology
HE stained tissue slides were re-evaluated using a light microscope (Leica DMLB microscope, 
Meyer Instruments Inc, Houston, Texas, USA) and classi!ed according to WHO classi!cation 
by two pathologists (Johanna Arola and Jaana Hagström) (2).
7.5.1 Adenomatous or goitrous nodule
Multiple nodules lacking a well-de!ned capsule with no di#erence from the surrounding 




A highly cellular tumour with evidence of increased proliferative activity as well as cellular 
and nuclear atypia, but lacking invasion to the capsule or a vessel, was classi!ed as atypical 
adenoma. (Figure 5A, B)
7.5.3 Oxyphilia
A tumour was considered oxyphilic if it was solely or predominantly (,75%) composed 
of oxyphilic cells. Oxyphilic cells were loosely cohesive with a moderate amount of deeply 
eosinophilic and granular cytoplasm and round nuclei. Growth pattern was either solid 
or trabecular with low amount of colloid present. Nuclei were large, hyperchromatic and 
pleomorphic with a prominent nucleoli. (Figure 5C)
 
7.5.4 Invasiveness
Invasive growth was required for the diagnosis of FTC. Invasive growth included vascular 
and capsular invasion. Vascular invasion was veri!ed within the vessels of the capsule or 
outside it, but not in the vessels inside the tumour. Either an endothelium-surrounded 
tumour cells as a thrombus or a penetrating mass indicated a vascular invasion. Capsular 
invasion was comprehended as a penetration of the tumour tissue through the capsule. It 
was distinguished from the penetration wound of FNAB (Figure 5D-G). Minimally invasive 
FTCs exhibited only focal invasion either to the capsule or a vessel, whereas widely invasive 
FTCs showed widespread in!ltration into adjacent thyroid tissue or into vessels.
7.5.5 Poor di#erentiation
PDFTCs were separated from well-di#erentiated FTCs (WDFTCs), with the former showing 
thyroglobulin positive tumour cells with a high proliferative activity (MIB-1 / PI index of 
10-30%). In PDFTCs, growth pattern was in!ltrative with either solid, trabecular or insular 
appearance. Foci of necrosis and mitoses were frequently present and vascular invasion 
was obvious. Tumour cells were dyscohesive and irregularly sized and only scant colloid 
was present. Nuclei were bland and usually monomorphic with !ne chromatin and small 
nucleoli (Figure 5H, I).
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Figure 5. A and B: HE stainings of atypical adenomas, original magni!cations of 40X and 10X. C: HE-staining 
of oxyphilic adenoma, original magni!cation 40X. D and F: HE-stainings showing an obvious vascular invasion 
with a penetrative manner (D) as well as a thrombus inside the vessel (F). Original magni!cations 10X. E and 
G: CD31 staining veri!es the presence of endothelium in invasions (!gure D corresponding to E and !gure F 
to G). Original magni!cations 10X. H and I: HE-staining of PDFTCs. Original magni!cations of 10X and 40X.
7.6     Process  of  immunohistochemistry
$rough immunohistochemical staining procedures a speci!c epitope of an antigen can 
be detected in a tissue specimen. $ese epitopes o*en need retrieval for exposing the 
immunogenic sites from cross-linking proteins and thus increasing the sensitivity of the 
method. In this study, the retrieval was performed using a pretreatment (PT) module of an 
Autostainer (LabVision UK, Ltd., Cheshire, UK) with a trishydroxymethylaminomethane 
hydrochloride (tris-HCl) bu#er or heated in a microwave in a citrate bu#er. A peroxidase-
blocking solution (methanol and hydrogen peroxidase) was used to destroy the endogenous 
peroxidase activity. Normal serum was used to block nonspeci!c staining. For antibody 
binding, we used the avidin-biotin complex (ABC) method. $is method involves three 
layers: the !rst layer is the unlabelled primary antibody, the second consists of the biotinylated 
secondary antibody (immunoglobulin G (IgG)) and the third is a complex of avidin-biotin 
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peroxidase or horseradish peroxidase (HRP), which is !nally bound with a speci!c substrate 
(3,3’-diaminobenzidine [DAB] or 3-amino-9-ethylcarbazole [AEC]) to produce a speci!c 
coloring of the specimen. Counterstaining was performed with Meyer´shaematoxylin.
An antibody can be either monoclonal (mAb) or polyclonal (pAb). $e mAbs are 
manufactured in cells that are identical to each other with a monovalent a)nity of binding 
to a single epitope. $ey are produced with a hybridoma technique by fusing myeloma cells 
with B cells from the spleen of a mouse that has been immunized with the antigen desired. 
On the other hand, pAbs are obtained from di#erent B cells identifying di#erent epitopes of 
a speci!c antigen. $e mAbs are more expensive, more time-consuming and more di)cult to 
produce than pAbs. $e mAbs are renewable, whereas pAbs are not. $e pAbs can amplify a 
low expression level of a target protein. Futhermore, they can be directed against an unknown 
antigen. However, they su#er from background signaling and cross-reactivity (177).
 
7.7     Tissue  microarray
For immunohistochemistry, a tissue microarray (TMA) block was constructed (II, III). 
Tumour core punctures were taken from two representative areas of the original para)n 
tumour blocks: one from the border and one from the central area of the tumour. Maximum 
of 56 cores were inserted into a recipient para)n block using a tissue microarrayer (Beecher 
Instruments, Silver Spring, MD, 
USA, MTABooster® Version 1.01 for 
Beecher Manual Arrayer, Alphelys). 
$ree sections from di#erent levels 
were cut from each TMA block to 
obtain nine spots per tissue sample 
for immunohistochemical analysis. 
(Figure 6).




7.8     Immunohistochemistry
Whole sections (I, IV) and TMA sections (II, III) were used. Formalin-!xed and para)n-
embedded tumour samples were cut into 4-nm sections and heated in 55°C for 2 hours. 
Slides were depara)nized in xylene, and rehydrated through graded alcohol series and 
destilled water and treated in a the PT of an Autostainer (LabVision) in either Tris–HCl 
bu#er (pH 8.5) or Tris-ethylenediaminetetraacetic (EDTA) bu#er (pH 9.0) for 20 min at 
98°C. Staining was performed in an Autostainer 480 (LabVision), using the Dako REAL 
EnVision Detection System, Peroxidase⁄DAB+, rabbit⁄mouse (Dako, Glostrup, Denmark). 
Before immunohistochemical staining, the slides were treated with 0.3% Dako REAL 
peroxidase-blocking solution for 5 min following incubation with a speci!c antibody 
(Table 7) in correct dilution for 1 h, using Dako REAL antibody diluent, followed by a 30-
min incubation with Dako REAL EnVision⁄HRP detection system, Rabbit⁄Mouse (ENV) 
reagent. Visualization was carried out by Dako REAL DAB+ Chromogen for 10 min. $e 
slides were washed with phosphate-bu#ered saline (PBS)-0.04%Tween20 between each step. 
Counterstaining was performed with Meyer’s haematoxylin, followed by washing in tap 
water for 10 min and mounted with mounting medium (Aquamount, BDH, Poole, UK). $e 
immunohistochemical staining procedure was performed similarly in each study, except for 
platelet endothelial cell adhesion molecule 1 (CD31/PECAM1).
$e immunostaining with CD31 antibody was done manually, using whole sections. A*er 
depara)nation and dehydration, the slides were treated in a microwave oven in citrate bu#er 
(pH 6.0) and then incubated in methanol and hydrogen peroxidase. A Vectastain Elite ABC 
kit (Vector Laboratories Inc., Burlingame, CA, USA) was used according to manufacturer´s 
instructions for immunostaining with CD31 antibody. AEC containing hydrogen peroxide 
was used for visualization of the antibody and Meyer’s haematoxylin for counterstaining. 
$e slides were mounted with aqueous mounting media (glycerol vinyl alcohol aqueous 
mounting solution; Zymed Laboratories, South San Francisco, CA, USA). A negative 
control for staining was received by omitting the primary antibodies during the procedure. 
$yroglobulin staining was performed to ensure the correct origin of the tumour as well as 
its viability.
 
7.9     Antibodies
A descriptive list of antibodies used (I-IV) are shown in Table 8. A novel monoclonal 
antibody named HES5 was used (II). It was produced by a collaborating laboratory (Christian 
Fermér and Olle Nilsson, Fujirebio Diagnostics AB). An undi#erentiated human embryonic 
(hES) stem cell line SA167 (Cellartis, Göteborg, Sweden) was used for immunization of the 
mice. Conventional hybridoma technology (178) was used to establish hybridoma cell lines 
producing monoclonal antibodies (mAbs) against hES cells. $e detailed description of the 
method is in the supplementary data of the study II.
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Table 8. Overview of antibodies in the study.
  
Antigen   Study   Antibody  
Antibody  
type   Manufacturer   Dilution  
Staining  
type  
Cyclin  D1   I   SP4   rabbit  mAb   Neomark   1:20   Nuclear  
p53   I   DO-­7   mouse  mAb   Dako   1:150   Nuclear  
Ki-­67   I,  III   MIB-­1   mouse  mAb   Dako   1:150   Nuclear  
PECAM-­1   I   CD31   mouse  mAb   Dako   1:100   Endothelium  
TLR2   IV   sc-­10739   rabbit  pAb   Santa  Cruz   1:50   Cytoplasmic  
TLR4   IV   sc-­10741   rabbit  pAb   Santa  Cruz   1:50   Cytoplasmic  
T200,  Ly-­5   II   CD45   mouse  mAb   Dako   1:750   Cytoplasmic  
ER    III   NCL-­L-­ER-­
6F11  
mouse  mAb   Novocastra   1:50   Nuclear  
ER    III   sc-­8974   rabbit  pAb   Santa  Cruz   1:100   Nuclear  
Thyroglobulin   III   Anti-­human  Tg   rabbit  pAb   Dako   1:2000   Cytoplasmic  
unknown   II   HES5   mouse  mAb   noncommercial   1:300   Nuclear  
                  Cytoplasmic  
Immunohistochemical staining
Two independent researchers (Annukka Heikkilä and Jaana Hagström) scored tumour 
specimens. $e researchers did not know the clinical status. Di#erent scoring categories 
were used for di#erent immunohistochemical stains (Table 8, Figure 7).
Whole-tissue specimens were stained with MIB-1 antibody (I, IV). $e nuclei were stained 
and scored as<2%, 2–5%, 5–10% and >10%. Tonsilla tissue was used as positive control 
tissue.
$e p53 antigen was also used to stain whole-tissue sections (I). $e nuclei were stained and 
scored as negative, 1–10%, 10–50% and >50%. Colon tissue was used as a positive control.
Futhermore, whole-tissue section were stained with Cyclin D1 (I). Nuclear staining was 
observed. $e samples were scored as negative, 1–10%, 10–50% and >50%. Tissue from the 
ventricle was used as a positive control.
CD31 was used as a marker for endothelium surrounding the vessels to identify vascular 
invasion (I). Whole-tissue sections were used. Scoring was either positive or negative.
A TMA construction was used and recipient slides were stained with HES5 antibody (II). 
Expression in cytoplasmic staining was scored as none, mild, moderate or strong, according 
to its intensity. Nuclear staining was scored by the percentage of positively stained nuclei, 




$e expression of ER& and ER% was studied, using the TMA method (III). $e 
immunohistochemical stainings were nuclear and were scored by the percentage of positive 
nuclei with a 5% accuracy. Mammary tissue was used as a positive control.
TLR-2 and TLR-4 expression was veri!ed from whole-tissue sections (IV). $e staining was 
cytoplasmic, with intensity of the expression scored as none, mild, moderate or strong.
CD45 from whole-tissue sections was scored as negative when none or only a few lymphocytes 
were present and positive when lymphocyte accumulations were seen (IV). Infected gingival 
tissue was used as the positive control.
$yroglobulin staining was scored as either negative or positive in identifying thyroid tissue. 
Omission of primary antibodies served as a negative control with each staining.
7.10     Statistical  analysis
$e associations between the various immunohistochemical stainings and clinicopathological 
variables were assessed by the chi-square test and Fisher´s exact test when number of cases was 
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Figure 7. Panel of all immunohistochemical 
markers studied. A. MIB-1, B. p53, C. Cyclin 
D1, D. CD31, arrows indicating an invasion 
of the tumour cells to a vessel, E. TLR-
2, F. TLR-4, G. abundant CD45-positive 
lymphocytes, H. HES5 nuclear positivity, I. 
HES5 cytoplasmic positivity, J. ER&, K. ER%, 
L. thyroglobulin positivity.
insu)cient. Survival time was calculated starting from date of the primary surgery to either 
last day of follow-up or either death due to other causes (censored cases) or cancer-related 
death, with survival curves constructed using the Kaplan-Meier method and compared with 
the log rank test. A p-value below 0.05 was con!ned as statistically signi!cant. Receiver – 
operating characteristic (ROC) curve analysis was used to compare the diagnostic value of 
HES5 to calculate the area under the curve (AUC) value. $e logistic regression model was 
used to evaluate whether two markers provided independent diagnostic information and 
whether their combination would improve accuracy. Statistical analyses were performed 
using SPSS 15.0 – 17.0 so*ware (SPSS Inc., Chicago, IL, USA / IBM – SPSS, Armonk, NY, 
USA).
7.11     Study  ethics
$e Surgical Ethics Comittee of HUCH and National Supervisory Authority of Welfare and 
Health (Valvira) approved the gathering of data from the Population Register Centre and 
the Hospital Discharge Registry. Statistics Finland gave permission to use the Cause of the 





8.1     Clinical  and  histological  characteristics  of  follicular  neoplasias
$e data on thyroid cancer incidence in Finland was received from Finnish Cancer Registry 
showing that during the past 30 years, the incidence of thyroid cancer has increased. $e 
increase is due to an increase in the incidence of PTC cases, while FTC cases have decreased 
(Figure 8). $is decrease was more evident in female patients, while the yearly number of 
new male patients remained nearly constant.
Figure 8. Number of new PTC and FTC patients from 1970 to 2004 in Finland (data from Professor Risto Sankila, 
Finnish Cancer Registry).
$e study material of follicular neoplasias diagnosed in the HUCH region was gathered over 
a time period of 20 years from 1990 until 2009. $e material included 44 FTC specimens, 
of which 37 (84%) were WDFTCs (mean age 56 years, 60 years for women, 55 years for 
men) and 7 (16%) were PDFTCs (mean age 59 years, 53 years for women, 61 years for men) 
(Figure 9). $e gender ratio for WDFTCs was 1.5:1 (22 women, 15 men) and for PDFTCs 
1:2.5 (2 women, 5 men). Of the WDFTCs, 10 (27%) were minimally invasive and 27 (73%) 
were widely invasive, whereas all 7 PDFTCs were widely invasive. Oxyphilia occurred in 15 
(34%) FTCs, two (2 of 7, 29%) of which were PDFTCs and the last 13 were WDFTCs (13 of 
37, 35%). Patients with minimally invasive disease (n=10, 23%) were free from metastasis 
and residives throughout the entire follow-up.
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A cohort of 20 (45%) FTC patients with aggressive disease with primary or secondary, 
regional or distant metastases were selected. $is group included all PDFTCs (n=7) as well 
as 13 WDFTCs with widely invasive growth patterns. Of 44 FTC patients, 7 (16%) developed 
primary metastasis and additional 7 developed secondary metastases. Recurrences emerged 
in 13 (30%) patients. Five patients showed nodal invasion at the time of diagnosis, and each 
had at least a T3 tumour of TNM staging (one T3, four T4, p=0.043, unpublished data). 
All carcinoma patients with primary distant metastasis (n=7) had tumours at least 4 cm in 
diameter, the average size being 7.6 cm. Size, age (both with various cuto# values) or gender 
did not correlate with the invasiveness of the tumour (minimally versus widely), nor with 
metastasis, di#erentiation level of the tumour or survival of all FTC patients (unpublished 
data).
Figure 9. Introducing HUCH region follicular thyroid carcinoma study material between 1990 to 2009 in "ow 
charts. Grey portion of boxes indicates the proportion of oxyphilic tumours in the group. Red line indicates the 
gender ratio (M = male, F = female, DOD = death of disease).
In all, 354 adenoma patients were diagnosed during the study period in the HUCH region, 
of which 287 were women and 67 were men (gender ratio 4.3:1). A total of 83 adenomas (66 
women and 17 men, gender ratio 3.9:1) were included in the study. A consecutive adenoma 
cohort was selected, consisting of typical adenoma patients (n=45, 36 women and 9 men, 
gender ratio 4:1). Each atypical (n = 9, 7 women and 2 men, gender ratio 3.5:1) and oxyphilic 
(n = 29, 23 women and 6 men, gender ratio 3.8:1) adenoma specimen was selected. Of all 
FTAs diagnosed in the HUCH region, oxyphilia occurred in 8% (29 of 354) (Figure 10). 
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Oxyphilia was statistically more common in FTCs than in FTAs when the entire HUCH 
population was acknowledged from 1990 to 2009 (p<0.001, unpublished data). $e mean 
size of all FTA tumours was 2.5 cm (range 0.2–7 cm), in women 2.6 cm (range 0.2–7 cm) 
and in men 2.1 cm (range 0.5+6 cm). $e FTAs were signi!cantly smaller than carcinomas 
(p<0.001, unpublished data).
Figure 10. Introducing HUCH region follicular thyroid adenoma study material between 1990 to 2009 in "ow 
charts. Grey portion of boxes indicates the proportion of oxyphilic tumours in the group. Red line indicates the 
gender ratio (M=male, F=female).
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8.2     Treatment  of  follicular  thyroid  neoplasias
All study patients underwent thyroid surgery at the Department of Surgery, HUCH. Surgical 
removal of the gland was performed conservatively, with minimal damage to adjacent tissues, 
including the laryngeal nerves and parathyroid glands. All carcinoma patients received 
radioiodine ablation a*er thyroidectomy, excluding one patient. Patients with advanced 
disease received additional radioiodine treatment, radiation, surgery or chemotherapy. $e 




Pat  no   Age   Sex   Oxy   Diff.   Vasc   Caps   Necr   Invas  
Size        
(cm)   T   N   M   Stage   MIB-­1   primM   secM  





Rad          





(yrs)   Status  
1   62   F   No   WDFTC   Yes   Yes   No   Wide   7   4   0   1   4   0-­2%  
Trachea,  
pleura   No   0   No   0   No   No   0.1   DOD  
2   50   M   Yes   PDFTC   Yes   Yes   No   Wide   8   4   1   1   4   25  %   Lungs   No   1   100   1   No   No   0.6   DOD  
3   73   F   No   PDFTC   Yes   Yes   No   Wide   10   4   1   0   4   10  %   No   Lungs   3   380   1   No   No   3.2   DOD  
4   57   F   No   WDFTC   Yes   Yes   No   Wide   4   2   0   1   4   0-­2%   Bone   No   5   730   3   No   No   4.2   DOD  
5   77   M   No   PDFTC   Yes   Yes   Yes   Wide   2,5   2   0   0   2   15  %   No   Bone   3   330   3   No   No   5.5   DOD  
6   54   M   Yes   WDFTC   Yes   Yes   No   Wide   8   4   1   0   4   5-­10%   No   Bone   4   470   3   ADR  
M   colli,  
trachea   7.4   DOD  
7   61   M   No   PDFTC   Yes   Yes   Yes   Wide   4   4   0   0   4   20  %   No   Lungs,  liver   2   180   1  
ADR,  
Gem   No   9.4   DOD  
8   67   F   No   WDFTC   Yes   Yes   Yes   Wide   8   3   0   1   4   0-­2%   Bone   No   4   550   3   No   No   12.6   DOD  
9   47   M   No   PDFTC   Yes   Yes   Yes   Wide   14   4   1   1   4   15  %  
Mediastinum,  
vena  cava   Bone,  lungs   3   370   3   ADR   No   2.7  
On-­
going  
10   72   M   Yes   PDFTC   Yes   Yes   No   Wide   5   3   0   0   3   15  %   No   Lungs   5   460   1   No   M  colli   4.1  
On-­
going  





cranii   6.5  
On-­
going  
12   49   M   No   WDFTC   No   Yes   No   Wide   4   2   0   0   2   2-­5%   No   Lungs,  bone   5   750   6   No   M  femoris   17.8  
On-­
going  
13   40   M   No   WDFTC   No   Yes   No   Wide   5   3   0   1   2   0-­2%   Brain   No   2   200   0   No   M  cerebri   11.4   Free  
14   52   F   Yes   WDFTC   Yes   Yes   No   Wide   2   1   0   0   1   2-­5%   No   No   1   100   0   No   No   14.7   Free  
15   72   F   No   WDFTC   Yes   Yes   No   Wide   7   3   0   0   3   2-­5%   No   No   2   250   0   No   No   18   Free  
16   52   M   Yes   WDFTC   Yes   Yes   No   Mini   2   1   0   0   1   5-­10%   No   No   2   230   0   No   No   18.3   Free  
17   56   M   No   WDFTC   No   Yes   No   Mini   3   3   0   0   3   0-­2%   No   No   2   250   0   No   No   19.3   Free  
18   40   F   No   WDFTC   Yes   Yes   No   Wide   2   1   0   0   1   0-­2%   No   No   1   100   0   No   No   19.7   Free  
19   45   M   No   WDFTC   Yes   Yes   No   Wide   4   2   0   0   2   5-­10%   No   No   5   730   1   No   No   19.9   Free  
20   76   F   Yes   WDFTC   No   Yes   No   Wide   3   2   0   0   2   5-­10%   No   No   1   120   0   No   No   20   Free  
21   48   M   No   WDFTC   No   Yes   No   Wide   6   3   0   0   3   2-­5%   No   No   1   100   0   No   No   20   Free  
22   63   F   No   WDFTC   No   Yes   No   Mini   4   2   0   0   2   0-­2%   No   No   2   230   0   No   No   20.5   Free  
23   50   F   No   WDFTC   No   Yes   No   Mini   0,6   1   0   0   1   0-­2%   No   No   1   100   0   No   No   20.6   Free  
24   69   F   No   WDFTC   Yes   Yes   No   Wide   8   4   0   1   4   2-­5%   Lungs   No   4   450   0   No   No   2.5   Free  
25   24   F   No   WDFTC   Yes   Yes   No   Wide   5   3   0   0   1   5-­10%   No   No   2   200   0   No   No   3.5   Free  
26   76   F   Yes   WDFTC   Yes   No   No   Mini   3   2   0   0   2   5-­10%   No   No   1   30   0   No   No   3.8   Free  
27   71   F   No   WDFTC   Yes   Yes   Yes   Wide   8   4   0   0   4   2-­5%   No   No   2   150   1   No   No   4.5   Free  
28   60   F   Yes   WDFTC   Yes   Yes   No   Wide   5   3   0   0   3   2-­5%   No   No   1   100   0   No   No   4.5   Free  
29   67   M   Yes   WDFTC   Yes   Yes   No   Wide   3   2   0   0   2   2-­5%   No   No   5   350   0   No   No   4.8   Free  
30   35   F   No   WDFTC   No   Yes   No   Wide   3   2   0   0   1   2-­5%   No   No   1   30   0   No   No   5.3   Free  
31   74   F   No   WDFTC   Yes   Yes   No   Wide   4   2   0   0   2   2-­5%   No   No   1   60   0   No   No   5.5   Free  
32   56   M   No   WDFTC   Yes   Yes   No   Wide   3   2   0   0   2   0-­2%   No   No   1   100   0   No   No   5.5   Free  
33   80   F   No   WDFTC   Yes   Yes   No   Wide   8   3   0   0   3   2-­5%   No   No   2   180   0   No   No   5.7   Other  
34   43   M   No   WDFTC   Yes   Yes   No   Mini   5   3   0   0   1   0-­2%   No   No   1   100   0   No   No   6   Free  
35   71   F   Yes   WDFTC   Yes   Yes   No   Wide   1   1   0   0   1   5-­10%   No   No   1   60   0   No   No   6.8   Free  
36   48   F   Yes   WDFTC   Yes   Yes   No   Wide   2,5   2   0   0   2   5-­10%   No   No   1   30   0   No   No   7   Free  
37   54   M   No   WDFTC   No   Yes   No   Mini   1   1   0   0   1   0-­2%   No   No   1   100   0   No   No   7   Free  
38   55   M   Yes   WDFTC   Yes   Yes   No   Mini   3   2   0   0   2   2-­5%   No   No   1   100   0   No   No   7.3   Free  
39   78   F   No   WDFTC   Yes   Yes   Yes   Wide   6   3   0   0   3   5-­10%   No   No   2   165   0   No   No   7.5   Free  
40   47   M   Yes   WDFTC   Yes   No   Yes   Mini   3   2   0   0   2   2-­5%   No   No   1   30   0   No   No   8.3   Free  
41   47   F   Yes   WDFTC   Yes   No   No   Mini   4   2   0   0   2   0-­2%   No   No   1   30   0   No   No   8.4   Free  
42   83   M   No   WDFTC   No   Yes   No   Wide   6   3   0   0   3   2-­5%   No   No   2   180   0   No   No   9.7   Other  
43   45   F   No   WDFTC   Yes   No   No   Wide   2   1   0   0   1   5-­10%   No   No   1   100   0   No   No   10.9   Free  
44   69   M   Yes   WDFTC   Yes   Yes   No   Wide   5   3   1   0   4   2-­5%   No   No   2   250   1   No   No   16.1   Other  
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Table 9. $erapies of all FTC patients in 
chronological order according to follow-up 
time within status groups. Abbreviations: 
Pat   no = patient number, Oxy = oxyphilia, 
Diff = di#erentiation type, WDFTC = well-
di#erentiated follicular thyroid carcinoma, 
PDFTC = poorly di#erentiated follicular 
thyroid carcinoma, Vasc = vascular invasion, 
Caps = capsular invasion, Necr = necrosis, 
Invas = invasiveness, Wide = widely invasive, 
Mini = minimally invasive, T = tumour = 
size of tumour, N =  nodus = lymph node 
metastasis, M = distal metastasis, PrimM 
= primary metastasis, SecM = secondary 
metastasis, RaI = radioiodine treatment, Rad 
= radiation therapy, Chemo = chemotherapy, 
ADR = Adriamycin, Gem = Gemcitabin, 
Second   surg = secondary surgery, DOD 
= death of disease, On-­going = on-going 
disease, Other = other cause of death.
  
Pat  no   Age   Sex   Oxy   Diff.   Vasc   Caps   Necr   Invas  
Size        
(cm)   T   N   M   Stage   MIB-­1   primM   secM  





Rad          





(yrs)   Status  
1   62   F   No   WDFTC   Yes   Yes   No   Wide   7   4   0   1   4   0-­2%  
Trachea,  
pleura   No   0   No   0   No   No   0.1   DOD  
2   50   M   Yes   PDFTC   Yes   Yes   No   Wide   8   4   1   1   4   25  %   Lungs   No   1   100   1   No   No   0.6   DOD  
3   73   F   No   PDFTC   Yes   Yes   No   Wide   10   4   1   0   4   10  %   No   Lungs   3   380   1   No   No   3.2   DOD  
4   57   F   No   WDFTC   Yes   Yes   No   Wide   4   2   0   1   4   0-­2%   Bone   No   5   730   3   No   No   4.2   DOD  
5   77   M   No   PDFTC   Yes   Yes   Yes   Wide   2,5   2   0   0   2   15  %   No   Bone   3   330   3   No   No   5.5   DOD  
6   54   M   Yes   WDFTC   Yes   Yes   No   Wide   8   4   1   0   4   5-­10%   No   Bone   4   470   3   ADR  
M   colli,  
trachea   7.4   DOD  
7   61   M   No   PDFTC   Yes   Yes   Yes   Wide   4   4   0   0   4   20  %   No   Lungs,  liver   2   180   1  
ADR,  
Gem   No   9.4   DOD  
8   67   F   No   WDFTC   Yes   Yes   Yes   Wide   8   3   0   1   4   0-­2%   Bone   No   4   550   3   No   No   12.6   DOD  
9   47   M   No   PDFTC   Yes   Yes   Yes   Wide   14   4   1   1   4   15  %  
Mediastinum,  
vena  cava   Bone,  lungs   3   370   3   ADR   No   2.7  
On-­
going  
10   72   M   Yes   PDFTC   Yes   Yes   No   Wide   5   3   0   0   3   15  %   No   Lungs   5   460   1   No   M  colli   4.1  
On-­
going  





cranii   6.5  
On-­
going  
12   49   M   No   WDFTC   No   Yes   No   Wide   4   2   0   0   2   2-­5%   No   Lungs,  bone   5   750   6   No   M  femoris   17.8  
On-­
going  
13   40   M   No   WDFTC   No   Yes   No   Wide   5   3   0   1   2   0-­2%   Brain   No   2   200   0   No   M  cerebri   11.4   Free  
14   52   F   Yes   WDFTC   Yes   Yes   No   Wide   2   1   0   0   1   2-­5%   No   No   1   100   0   No   No   14.7   Free  
15   72   F   No   WDFTC   Yes   Yes   No   Wide   7   3   0   0   3   2-­5%   No   No   2   250   0   No   No   18   Free  
16   52   M   Yes   WDFTC   Yes   Yes   No   Mini   2   1   0   0   1   5-­10%   No   No   2   230   0   No   No   18.3   Free  
17   56   M   No   WDFTC   No   Yes   No   Mini   3   3   0   0   3   0-­2%   No   No   2   250   0   No   No   19.3   Free  
18   40   F   No   WDFTC   Yes   Yes   No   Wide   2   1   0   0   1   0-­2%   No   No   1   100   0   No   No   19.7   Free  
19   45   M   No   WDFTC   Yes   Yes   No   Wide   4   2   0   0   2   5-­10%   No   No   5   730   1   No   No   19.9   Free  
20   76   F   Yes   WDFTC   No   Yes   No   Wide   3   2   0   0   2   5-­10%   No   No   1   120   0   No   No   20   Free  
21   48   M   No   WDFTC   No   Yes   No   Wide   6   3   0   0   3   2-­5%   No   No   1   100   0   No   No   20   Free  
22   63   F   No   WDFTC   No   Yes   No   Mini   4   2   0   0   2   0-­2%   No   No   2   230   0   No   No   20.5   Free  
23   50   F   No   WDFTC   No   Yes   No   Mini   0,6   1   0   0   1   0-­2%   No   No   1   100   0   No   No   20.6   Free  
24   69   F   No   WDFTC   Yes   Yes   No   Wide   8   4   0   1   4   2-­5%   Lungs   No   4   450   0   No   No   2.5   Free  
25   24   F   No   WDFTC   Yes   Yes   No   Wide   5   3   0   0   1   5-­10%   No   No   2   200   0   No   No   3.5   Free  
26   76   F   Yes   WDFTC   Yes   No   No   Mini   3   2   0   0   2   5-­10%   No   No   1   30   0   No   No   3.8   Free  
27   71   F   No   WDFTC   Yes   Yes   Yes   Wide   8   4   0   0   4   2-­5%   No   No   2   150   1   No   No   4.5   Free  
28   60   F   Yes   WDFTC   Yes   Yes   No   Wide   5   3   0   0   3   2-­5%   No   No   1   100   0   No   No   4.5   Free  
29   67   M   Yes   WDFTC   Yes   Yes   No   Wide   3   2   0   0   2   2-­5%   No   No   5   350   0   No   No   4.8   Free  
30   35   F   No   WDFTC   No   Yes   No   Wide   3   2   0   0   1   2-­5%   No   No   1   30   0   No   No   5.3   Free  
31   74   F   No   WDFTC   Yes   Yes   No   Wide   4   2   0   0   2   2-­5%   No   No   1   60   0   No   No   5.5   Free  
32   56   M   No   WDFTC   Yes   Yes   No   Wide   3   2   0   0   2   0-­2%   No   No   1   100   0   No   No   5.5   Free  
33   80   F   No   WDFTC   Yes   Yes   No   Wide   8   3   0   0   3   2-­5%   No   No   2   180   0   No   No   5.7   Other  
34   43   M   No   WDFTC   Yes   Yes   No   Mini   5   3   0   0   1   0-­2%   No   No   1   100   0   No   No   6   Free  
35   71   F   Yes   WDFTC   Yes   Yes   No   Wide   1   1   0   0   1   5-­10%   No   No   1   60   0   No   No   6.8   Free  
36   48   F   Yes   WDFTC   Yes   Yes   No   Wide   2,5   2   0   0   2   5-­10%   No   No   1   30   0   No   No   7   Free  
37   54   M   No   WDFTC   No   Yes   No   Mini   1   1   0   0   1   0-­2%   No   No   1   100   0   No   No   7   Free  
38   55   M   Yes   WDFTC   Yes   Yes   No   Mini   3   2   0   0   2   2-­5%   No   No   1   100   0   No   No   7.3   Free  
39   78   F   No   WDFTC   Yes   Yes   Yes   Wide   6   3   0   0   3   5-­10%   No   No   2   165   0   No   No   7.5   Free  
40   47   M   Yes   WDFTC   Yes   No   Yes   Mini   3   2   0   0   2   2-­5%   No   No   1   30   0   No   No   8.3   Free  
41   47   F   Yes   WDFTC   Yes   No   No   Mini   4   2   0   0   2   0-­2%   No   No   1   30   0   No   No   8.4   Free  
42   83   M   No   WDFTC   No   Yes   No   Wide   6   3   0   0   3   2-­5%   No   No   2   180   0   No   No   9.7   Other  
43   45   F   No   WDFTC   Yes   No   No   Wide   2   1   0   0   1   5-­10%   No   No   1   100   0   No   No   10.9   Free  
44   69   M   Yes   WDFTC   Yes   Yes   No   Wide   5   3   1   0   4   2-­5%   No   No   2   250   1   No   No   16.1   Other  
Results
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8.3     Immunohistochemistry
8.3.1 Non-neoplastic lesions
A novel monoclonal stem cell marker HES5 was studied and a signi!cant correlation was 
found, with expression di#ering between non-neoplastic, e.g. goitrous, hyperplastic and 
normal thyroid tissue, and neoplastic follicular thyroid tissue (II). Nuclear expression of 
HES5 was more marked in non-neoplastic lesions, whereas cytoplasmic expression was 
stronger in neoplastic lesions (Table 10). Nuclear expression was a more sensitive and 
speci!c trait than cytoplasmic staining in predicting the likelihood of a neoplasia.  Using 
ROC curve analysis, the AUC value was higher for nuclear staining than for cytoplasmic 
staining (AUCnucleus=0.752, 95% con!dence interval (CI) 0.686+0.818 versus 
AUCcytoplasm=0.681, 95% CI 0.608+0.754).
Table 10. Expression of HES5 in study material.
  HES  5  –  amount  of  nuclei  
stained,  n  (%)   0  %   1 35%   36 75%   >75%  
all  FTC  (n=42)   29  (69)   4  (10)   3  (7)   6  (14)  
all  FTA  (n=82)   46  (56)   19  (23)   7  (9)   10  (12)  
goitre  (n=41)   4  (10)   15  (37)   13  (32)   9  (22)  
hyperplasia  (n=22)   3  (14)   8  (36)   8  (36)   3  (14)  
normal  (n=23)   2  (9)   11  (48)   8  (35)   2  (9)  
  
HES   5   –   intensity   of  
cytoplasmic  staining,  n  (%)   zero   mild   moderate   strong  
all  FTC  (n=42)   2  (5)   12  (29)   15  (36)   13  (31)  
all  FTA  (n=82)   3  (4)   31  (38)   29  (35)   19  (23)  
goitre  (n=41)   0  (0)   22  (54)   19  (46)   0  (0)  
hyperplasia  (n=22)   1  (5)   19  (86)   2  (10)   0  (0)  




Several markers in our studies di#erentiated between FTA and FTC. Of 44 FTCs and 83 
FTAs, a signi!cant correlation was detected with MIB-1/Ki-67 expression, showing a higher 
expression in FTCs (p<0.001, unpublished data).
Cyclin D1 expression was higher in FTCs than in FTAs (I, p=0.001). $e expression showed 
no signi!cant correlation with clinical parameters nor with survival (p=0.640, unpublished 
data) (Table 11).
ER% expression di#ered signi!cantly between FTAs and FTCs, with FTAs exhibiting a stronger 
expression (II) (Table 11). Logistic regression analysis showed that ER% is more sensitive, 
with an odds ratio of 0.85 (95% CI 0.79+0.92, p<0.001), as a di#erential marker between 
FTA and FTC than MIB-1 (p=0.018). ROC curve analysis showed that the diagnostic value 
of ER% is again stronger than that of MIB-1 (AUC 0.757 versus 0.677) in our material (III). 
Combining ER% and MIB-1 expressions resulted in no additional bene!t for di#erential 
diagnosis, as calculated with a cancer probability index. No signi!cant correlation was 
detected between genders with ER& or % expressions (unpublished data).
A di#erence in expression between benign and malignant tissues with TLR-2 was shown 
(IV), with a stronger expression in adenomas (p=0.013), although this marker showed no 
signi!cant correlation with other signi!cant clinical parameters (Table 11).
Table 11. Expression of immunohistochemical markers used (I, III and IV).
  MIB-­1,  n(%)   0 2%   2 5%   5 10%   >10%  
FTC  (n=44)   12(27)   15(34)   10(23)   7(16)  
FTA  (n=83)   43(52)   26(31)   14(17)   0(0)  
Cyclin  D1,  n(%)   0 10%   10 50%   50 80%   80 100%  
FTC  (n=39)   13(33)   20(51)   6(15)   0(0)  
FTA  (n=51)   21(41)   25(41)   5(10)   0(0)  
p53,  n(%)   0 10%   10 50%   50 80%   80 100%  
FTC  (n=39)   34(87)   4(10)   1(3)   0(0)  
FTA  (n=51)   45(88)   4(8)   2(4)   0(0)  
TLR-­2,  n(%)   none   mild   moderate   strong  
FTC  (n=44)   1(2)   30(68)   13(30)   0(0)  
FTA  (n=83)   1(1)   38(46)   35(42)   9(11)  
TLR-­4,  n(%)   none   mild   moderate   strong  
FTC  (n=44)   3(7)   21(48)   14(32)   6(14)  
FTA  (n=83)   1(1)   30(36)   33(40)   19(23)  
ER ,  n(%)   0%   <1%   5%   10%  
FTC  (n=43)   40(93)   2(5)   0(0)   1(2)  
FTA  (n=82)   73(89)   9(11)   0(0)   0(0)  
ER ,  n(%)   0%   <1%   5%   10%  
FTC  (n=42)   4(10)   7(17)   6(14)   25(60)  
FTA  (n=82)   1(1)   3(4)   2(2)   76(93)  
Results
60
8.3.3 Aggressive follicular thyroid carcinomas
PDFTCs showed a higher MIB-1 expression/PI than WDFTCs (p<0.001) and metastatic 
tumours (primary and/or secondary, p=0.001), while aggressively acting tumours also 
showed higher PI (p=0.021) (I). MIB-1 showed no correlation with survival (p=0.094) when 
the original scoring pattern was used. However, when group from 0% to 5% was combined, 
a statistically signi!cant correlation was achieved between MIB-1 expression and survival 
(p=0.007, Figure 11, unpublished data). With a cuto# point of 10%, e.g. between WDFTC 
and PDFTC, a stronger correlation was found (p<0.001, unpublished data) with patients 
with high PI having a 5-year survival of 69% versus those with a low PI 94%.




I failed to detect any correlation with the tumour material examined and p53 expression, 
because the majority of all neoplasias studied showed negative or mild expression, even 
in the PDFTCs (I). No prognostic correlation was achieved with p53 expression (p=0.903, 
unpublished data).
$e data concerning patients´ stimulated serum thyroglobulin levels prior to the !rst 
radio ablation was gathered and a signi!cant correlation was found between high 
levels of thyroglobulin and poor survival (unpublished data, Figure 12). Patients with 
antithyroglobulin antibodies were excluded.




$e expression of ER% was evaluated (III) and a correlation was found with poor prognosis, 
since each  patient su#ering a death from disease exhibited a score of -5% positive cells in 
their tumours (p=0.003, IV). Patients with tumours showing -5%expression had a 5-year 
survival of 78%, whereas all patients in the group of high expression were alive at the end of 
follow-up. Using a cuto# of -5% of the ER% score, nonmetastasized tumours were more o*en 
positive than metastasized (either primary or secondary) tumours (p=0.035, unpublished 
data). No correlation was found between primary and secondary metastasized tumours 
(p=0.608, unpublished data). Expression of ER% in WDFTCs was evidently stronger than in 
PDFTCs, although the di#erence was not statistically signi!cant, most likely due to the small 
number of cases (III) (Figure 13).
Figure 13. ER% expression in WDFTC and PDFTC cases in a box plot !gure. $e whiskers represent extreme 
values, edges of boxes quartiles and bold line the median value.
It was also found that chronic in"ammation (CD45-positive lymphocytes) in tissue adjacent 
to tumours exhibiting distant metastases was diminished compared with nonmetastasized 
tumours (p=0.031). In tumours of male FTC patients, chronic in"ammation was more 




9     DISCUSSION
9.2     Clinicopathological  features  of  follicular  thyroid  neoplasias
Gender and age
$e FTC material of the present study consisted of 24 women and 20 men, resulting in a 
gender ratio of 1.2:1. Other studies showed that thyroid carcinoma, including all subtypes, 
is 3-fold more common in women than in men (35,36), whereas FTC alone is about 2- 
to 4-fold more commonly seen in women (49,179,180). In PDFTCs, the gender ratio was, 
contrasted with that of FTCs, with a male predominance of 1:2.5 (2 women, 5 men). $is 
is in accordance with other studies, since the male gender is o*en believed to be a poor 
prognostic trait, with PDTCs previously being classi!ed in other thyroid cancer groups 
(181,182). However, the number of PDFTCs was small (n=7), thus causing possible bias. 
$e entire adenoma group diagnosed in HUCH region included 287 women and 67 men 
with a gender ratio 4.3:1, in line with previous results (15).
$e reasons for female preponderance in thyroid lesions are unknown. It has been explained 
by female hormonal and reproductive factors. Pregnancy and early menopause seem to 
enhance the risk of thyroid tumorigenesis (5,183). It has been speculated that women take 
better care of their health than men, which leads to earlier discovery of tumours in their 
benign phase and thus preventing the progression to carcinoma. If a classical multistep 
tumorigenesis pathway of an FTC arising from an FTA and in some cases even from a 
goitrous nodule is accepted, this may in part explain why the gender ratio in FTC in the 
present study was nearly equal instead of showing female preponderance.
In the present study, FTC patients (mean age 58 years) were older than FTA patients (mean 
age 49 years) at the time of diagnosis. One could speculate that a carcinoma takes a longer 
time to develop than an adenoma, since carcinomas are believed to evolve from adenomas. 
$e WHO worldwide data on thyroid cancer shows that the FTC incidence peaks in the !*h 
decade (49), in line with the present study. PTC peaks in the fourth decade of life (40).
Size
In the present study, the carcinomas were on average larger than the adenomas (mean size 
4.6 cm versus 2.5 cm, respectively). Again, this is in line with the multistep tumorigenesis of 
FTC developing from an adenoma in a progressive manner. $e WHO showed that a tumour 
size exceeding a diameter of 4 cm is an adverse prognostic factor for WDFTCs correlating 
with extrathyroidal growth, multifocality, regional and distant metastases (49,184). A size 
over 4 cm has correlated with poor prognosis in FTC in previous studies as well (185). All 
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patients with primary distant metastases (n=7) had a tumour size over 4 cm in diameter, the 
average size being 7.6 cm, although size did not correlate with the invasiveness of the tumour, 
nor with metastases, di#erentiation level of the tumour or survival. In FTC, a tumour size 
greater than 4 cm (T3 in TNM staging) is associated with lymph node metastasis, an event 
that is rare in encapsulated FTCs. Lymph node metastases are believed to occur once the 
tumour has grown enough in size to break through the capsule and spread via the lymphatics 
(184,186). Evidently, these tumours are widely invasive and thus have a poorer prognosis 
than smaller carcinomas. In the present study, !ve patients had nodal invasion at the time of 




$e tumour material consisted of 15 oxyphilic FTCs (34% of all FTCs) and of 29 oxyphilic 
FTAs (8% of all FTAs), showing that oxyphilia is more common in carcinomas. Oxyphilic 
tumours harbour mutations in mitochondrial DNA, in"icted by high levels of oxidative 
stress in thyroid cells. $is leads to energy production defects and to a production of excess 
amounts of dysfunctional mitochondria as a compensatory mechanism. Alterations in 
mitochondrial DNA increase susceptibility to thyroid tumorigenesis (187). Acquisition of an 
oxyphilic appearance is time-consuming and oxyphilic cell transformation is believed to be 
a continuous process. $is goes in line with observations showing more oxyphilia in FTCs, 
which are believed to evolve from FTAs, according to the classical multistep carcinogenesis 
concept. Patients with oxyphilic carcinomas showed similar survival compared with their 
nonoxyphilic counterparts. Oxyphilia, as well as in"ammation, are associated with high 
levels of oxidative stress. $us, instead of causing malignant transformation, it may simply 
be a consequence of oxidative metabolism, since similar survival !gures for oxyphilic and 
nonoxyphilic carcinomas have been shown in other studies as well (187). On the other hand, 
oxyphilia is associated with a poorer ability to concentrate iodine, which makes oxyphilic 
tumours less responsive to radioiodine therapy (187).
Poorly di#erentiated thyroid carcinoma
In 2004, the WHO introduced PDTC, a new entity in the spectrum of thyroid neoplasias 
(64). $us, the incidence numbers prior to 2004 are largely unknown. $e WHO stated that 
the incidence of PDTC may be up to 4+7% of diagnosed thyroid carcinomas. Both lower and 
higher !gures have been reported: 1% in Japan, 6% in the United States and 7+13% in Italy 
(63,130,188,189). Such variance in the incidence numbers is probably caused by the di#erent 
de!nitions used, such as diversities shown between WHO de!nition and Turin proposal, 
with the latter having more strict criteria (130). Geographical reasons are also considered, 
due to the high variance between countries; US 1.8% versus Italy 7% (130). $e role of iodine 
de!ciency has been suggested as one possible reason (130). In the present study, 16% of 
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FTCs were PDFTCs (7 of 44 patients). Among PTCs, the prevalence is as low as 1% (63,190). 
Apparently, it seems that FTC is more prone to dedi#erentiate into PDTC than PTC.
9.2     Immunohistochemistry
9.2.1 Non-neoplastic lesions
Several markers have been studied to di#erentiate between follicular neoplasias and non-
neoplastic lesions of the thyroid. Markers such as e-cadherin, syndecan-1, CK-19, galectin-3, 
HBME-1 and RAS have shown signi!cant correlation, but none show su)ciently high enough 
values for sensitivity and speci!city or adopted a signi!cant role in the clinical diagnostics 
(58,123,191-193).  Clinically, the di#erentiation between a non-neoplastic and a neoplastic 
thyroid lesion is important, because recommended management of neoplastic thyroid 
lesions is surgery, whereas non-neoplastic lesions need only to be kept under surveillance 
(27). Further research is needed, because thyroid nodules are common in population and 
the increasing use of modern imaging methods has led to an increasing number of small 
lesions detected either by purpose or incidentally.
A novel antibody HES5 was studied (II) that had not been published or described previously. 
HES5 expression di#ered signi!cantly between non-neoplastic and neoplastic follicular 
thyroid lesions. Nuclear expression of HES5 was stronger in non-neoplastic lesions, whereas 
cytoplasmic expression was more marked in neoplastic lesions. Nuclear expression of 
HES5 more sensitive and spesi!c than cytopasmic staining in predicting the likelihood 
of neoplasia. However, the expression showed too low a level of sensitivity and negative 
predictive values for it to be used alone in di#erential diagnostics, but as part of a panel of 
immunohistochemical markers it may be of bene!t.
Experiments so far have failed to unravel the antigen of the HES5 antibody against a human 
embryonic stem cell line. $e function of this antigen in the cell and in tumorigenesis of 
follicular thyroid neoplasias is also unknown, although the !ndings of this study indicate a 
role in early tumorigenesis. $e !ndings of this new stem cell marker distinguishing between 
thyroid non-neoplasia and neoplasia suggest that in addition to the classical multistep model, 
the more recently presented CSC theory may also play a role in thyroid carcinogenesis.
Interestingly, 4 out of 41 goitrous lesions in the study material showed negative nuclear 
staining for HES5, which may indicate the neoplastic nature of these lesions, although none 
showed strong cytoplasmic staining. In a study by Derwahl et al. (194), goitre is believed 
to be a true neoplasia that arises from a small group of functionally and structurally 
heterogeneous thyrocytes having a high intrinsic and autonomous growth potential, which 
secures the proliferation of new follicles and thus the basal secretion of thyroid hormones. 
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$ese cells may be a#ected by the overexpression of an oncogene or a growth factor, leading 
to formation of a tumour (194). $e genetic predisposition of developing nontoxic MNG is 
linked to a gene locus on chromosome 14q, and this predisposition is also associated with 
thyroid cancer formation (195). Normal thyroid tissue is polyclonal whereas hyperplastic or 
goitrous tissue can be both monoclonal and polyclonal, and malignant tissue monoclonal 
(196-198). $us clonality of the tissue cannot distinguish between hyperplasia and neoplasia 
(198). For example thyroid carcinoma is thought to originate as a monoclonal tumour that 
can progress to polyclonal tumour as secondary genetic alterations occur (74). It has been 
proposed that an adenoma might evolve from a goitrous nodule trough a hyperplastic process 
with more rapidly and autonomously proliferating cells leading to somatic mutations and 
eventually tumour development (199,200).
9.2.2 Neoplastic lesions
Several factors, including goitre, adenoma and in"ammation, promote development of 
thyroid cancer (59,156,158). By understanding the path of thyroid carcinogenesis, the 
various factors involved have been investigated to !nd a marker for di#erentiating between 
benign and malignant thyroid lesions. In the present study, the markers MIB-1, Cyclin D1, 
ER% and TLR-2 di#erentiated between FTA and FTC.
$e MIB-1/Ki-67 and Cyclin D1 markers, indicating the ability of tumours to proliferate and 
supporting the classical multistep carcinogenesis pathway, were both expressed more strongly 
in FTCs than in FTAs. Still, the expression of Cyclin D1 showed no signi!cant correlation with 
clinical parameters or with survival. $e most promising markers in di#erentiating between 
FTA and FTC in the present study, were MIB-1 and ER%. Currently, MIB-1 is in clinical use 
to assess the proliferation of tumour; in thyroid carcinomas it is most o*en used in evaluation 
of PDTC and ATC (103-105,113,136). Logistic regression and ROC curve analyses showed 
that ER% is stronger as a di#erential marker between FTA and FTC than MIB-1. On the other 
hand, ER% showed too low a level of sensitivity and speci!city for being used alone, but it 
may be exploited as part of a panel of markers. In the present study, the higher expression of 
ER% in FTAs than in FTCs suggests that classical multistep pathway is valid in the follicular 
carcinogenesis of thyroid. $e results go in line with ER% being acknowledged as a tumour 
suppressor important in maintaining the cell´s di#erentiated and epithelial phenotype. ER&, 
which induces cell proliferation and invasiveness of thyroid cancer cells, was unfortunately 
expressed only weakly, with no signi!cant correlation with clinicopathological characteristics 
in the present study (140,201-203). If expression of markers, such as ER% and MIB-1, were 
evaluated from thyroid cytology specimens, it would lead to higher speci!city of FNAB, to 
earlier and more reliable diagnosis and could save money and time.
TLR-2 and TLR-4, factors involved in in"ammatory reactions, were studied (IV). Only TLR-
2 di#erentiated signi!cantly between FTA and FTC, but showed no correlation with major 
clinicopathological characteristics of tumours.
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9.2.3 Aggressive follicular thyroid carcinomas
Although FTC o*en acts indolently, it is important to distinguish those patients with an 
aggressive disease as early as possible to direct them to a more thorough management. $e 
markers MIB-1, ER%, CD45 and TLR-4 showed prognostic value, thereby detecting those 
patients that might need more aggressive treatment (I, III, IV). No correlation was detected 
between p53 expression and clinicopathological features, since the majority of all neoplasias 
studied showed negative or mild expression, even in the PDFTCs (I). In other studies, p53 
expression was positive in 20+30% of cancer cells in PDTC (64), whereas in this study 
material all PDFTCs showed a score below 20% of positive cells.
$e results of ER% and MIB-1 (I, II) support the theory of multistep carcinogenesis, i.e. 
PDFTC to origin from WDFTC, since signi!cant di#erence in expressions were shown 
between the di#erentiation levels of the tumours. Both markers showed a signi!cant 
correlation with poor survival. All patients who died from disease exhibited a diminished 
level of ER% expression (III). ER% is believed to protect against hyperproliferation and its 
loss is linked tumour dedi#erentiation and progression. A prognostic association was also 
detected in breast, ovarian cancer and lung cancers (141-143). $e results of the present study 
suggest the clinical value of MIB-1 and ER% in preoperative risk management of patients.
Neither ER& or % expressions showed any di#erences between the genders, suggesting 
again a unisex purpose for these receptors. An interesting observation was also made, in 
which male patients´ tumours exhibited fewer in"ammatory cells in the adjacent tissue than 
female patients´ tumours (IV). $yroid cancer is approximately three times more common 
in women, but more aggressive cancers are more o*en encountered in men and the male 
gender is a well-known risk factor for poor prognosis (181,182), although no prognostic 
di#erence was observed between the genders in this study. $us, one might ponder on 
whether the female gender is a protective feature in thyroid carcinomas, perhaps explained 
by di#erences in estrogen hormone levels, other biological di#erences or di#erences in 
behaviour concerning health issues.
Chronic in"ammation is a major factor in human tumorigenesis (150,151). $e chronic 
presence of in"ammatory cells, various free radicals, chemokines and growth factors is able 
to alter normal cell homeostasis, leading to genomic instability to oncogenes and tumour 
suppressor genes (163,204). On the other hand, the presence of protective immune cells, 
such as lymphocytes and dendritic cells, is associated with better survival in thyroid cancer 
(157).
TLRs, important in in"ammatory reactions, are considered as a double-edged sword in 
cancer, with both promoting and inhibiting e#ects (169). $e results concerning TLR-
4 expression show that aggressiveness of tumour correlates with a dual staining pattern, 
either moderate to strong or absent expression. Non-aggressive tumours expressed TLR-4 
only mildly in the present study. Indeed, increased expression of TLR-4 has been associated 
with malignancy, poor di#erentiation and poor survival in lung, rectal and breast cancer 
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(205-208), whereas contrasting, i.e. decreased expression is linked to malignancy and poorer 
outcome in colon and prostate cancer (209,210). Such diverse e#ects may be caused by a 
dysfunctional receptor failing to awaken immune reaction against unknown neoplastic cells, 
but on the other hand lack of expression leads to a failure to recruit immune cells.
9.3     Study  limitations
FTC is a rare cancer type. Approximately 350+400 new thyroid cancer cases are diagnosed 
yearly in Finland, with a population of 5.4 million (31). About 10% of all thyroid cancer 
cases are FTCs (35+40 cases per year). In the HUCH region, with approximately 1.1 million 
residents, the approximate number of FTCs diagnosed currently per year is 7+8 new cases. 
And when the incidence rate of new FTC cases decreasing by an average of 15% in 20 years 
according to the Finnish Cancer Registry is considered, the cancer material in the present 
study showed a lower number than suspected. $e reasons for this discrepancy may be due 
to inaccurate categorization, since currently the guideline is to carefully sample the capsule 
of follicular neoplasias for possible invasions. But inaccurate data given to the Registry, 
regional di#erences in diagnostic criteria, as well as surgery performed in the private 
healthcare sector may also obscure the true number of FTCs in the HUCH region and in 
Finland.
FTC is an o*en indolently behaving cancer type; thus not many disease-related deaths are 
available. $us, this material is unique with eight disease-related deaths, due to its small size, 
chance or bias must be acknowledged in interpreting results. It would be of great interest 
to gather a larger multicenter cohort of FTCs to restudy the antibodies of interest to obtain 
more reliable and less-biased results.
$e immunohistochemistry method used is a remarkably sensitive and speci!c method 
used for the past 50 years to study the antigenic expression of cells and tissues, with feasible 
morphological preservation of histological and cytological samples. $e negative aspects 
of immunohistochemistry include the risk of false-negative results, due to inappropriate 
antibody, autolysis of antigen, antigen density below the detection capacity, and false-positive 
results, due to cross-reactivity of the antibody, nonspeci!c binding, endogenous peroxidase 
present, entrapment of normal cells inside the tumour and entrapment of proteins of normal 
cells inside the tumour cells (211).
Whole tissue sections (I, IV) and TMA sections (II, III) were used. Use of whole-tissue 
sections requires a large quantity of tumour material, thus diminishing the future use of 
the same material, which is especially unfortunate, considering the rare tumour material 
of FTCs. Additionally, tumours, especially carcinomas of poor di#erentiation, o*en have 
heterogenic areas of di#erentiation level. For example, in using the MIB-1 stain, analysis 
is made from hot spots of the tumour, i.e. the most actively proliferating areas. To obtain 
Discussion
69
equal proliferation rates, as in whole-tissue sections, stains such as MIB-1 should not be 
assessed from TMA sections. $e TMA procedure is thus mostly valid when antibody is 
expressed simultaneously throughout the section and the role of intratumour heterogeneity 
is further diminished by taking specimens from the peripheral and central areas of the 
tumour. Studies have shown that a strong correlation exists between TMA sections and 
whole-tissue sections; using large cohorts of tumour material, the reliability of the marker 
studied is further increased (212). $e present study, with only 44 cancers and 83 adenomas, 
thus includes the risk of bias, due to the small number of cases.
In comparison to whole-section analysis, TMA´s obvious bene!t is the feasibility of studying 
large quantities of tumours in a time-saving and cost-saving manner, and the staining quality 
is consistent between each spot. On the other hand, TMA is prone to disturbance by the 
quality of the tissue, which was also evident in this study, since thyroid tissue consists of 
major amounts of colloid, which easily causes the tissue to only loosely attach to the slide. 
Excellent technical skills are also required for use of TMA machinery.
9.4     Tumorigenesis  of  follicular  thyroid  tumours
$e results of the present study showed that at least two major pathways for follicular thyroid 
tumorigenesis are applicable. A novel stem cell marker HES5 reinforces the role of the 
stem cell theory in the tumorigenesis of follicular thyroid neoplasia evolving from a non-
neoplastic lesion. On the other hand, several markers of the present study support classical 
multistep tumorigenesis, with an FTC evolving from an FTA and further a PDFTC from a 
WDFTC. $e results showed that these theories do not contrast with each other, and further 
studies are needed for more detailed results.
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10     CONCLUSIONS
$e aim was to obtain diagnostic aid in the !eld of follicular thyroid neoplasia. $is material 
included 44 FTCs  (7 PDFTCs), 83 FTAs and 86 non-neoplastic thyroid lesions as a control 
group.
$e major !ndings were:
1) Clinicopathological re-evaluation
  
   Oxyphilic  tumour  cells  were  more  commonly  found  in  carcinomas  than  
adenomas




3) Speci!c immunohistochemical markers correlated signi!cantly:
  
lesions
   High nuclear expression in non-neoplastic lesions
   High cytoplasmic expression in neoplastic lesions
  
   Higher MIB-1 and Cyclin D1 expressions in FTCs than in FTAs
   Lower TLR-2 and ER% expressions in FTCs than in FTAs
  
   Both negative and high expressions correlating with aggressiveness
  
   High MIB-1 and low ER% expressions correlating with poor prognosis
 
In conclusion, the markers presented in this thesis can be used as an aid in the diagnosis 
of follicular thyroid lesions in revealing their neoplastic and malignant nature, as well as 
pointing to patients with high risk of aggressive and even fatal disease.
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